Publications
Since conception in 2007, the International Psoriasis & Arthritis Research Team has collaborated and published leading research in the fields of genomics, inflammation, immunology, and epidemiology.
This page contains a comprehensive and up-to-date list of journal articles, abstracts, and reports associated with IPART. You may search or sort publications by author(s), year, title, and journal name.
| Cover Art | Year | Title | Author(s) | Journal | Link | |
|---|---|---|---|---|---|---|
 | 2014 | Predictors for radiological damage in Psoriatic Arthritis. Results from a Single centre. | Bond SJ, Farewell VT, Schentag CT, Gladman DD. | Ann Rheum Dis 2007;66:370-376. | ||
| 2007 | A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? 56:840-849. | Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. | Arthritis Rheum | ||
| 2007 | Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale is valid in patients with Psoriatic Arthritis (PsA). | Chandran V, Bhella S, Schentag C, Gladman DD. | Ann Rheum Dis 2007;66:936-939 | ||
 | 2007 | Psoriasis Triggered by Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatologic Conditions, | de Gannes GC, Ghoreishi M, Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M, DUTZ JP, | Arch Dermatol. 2007 Feb;143(2):223-31. | ||
 | 2007 | Outcome measures in psoriatic arthritis (PsA). | Gladman DD, Mease PJ, Healy P, Helliwell PS, FitzGerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Rithclin C, Taylor W, Stand V. | J Rheumatol 2007;34:1159-1166. | ||
| 2007 | Consensus on a core set of domains for psoriatic arthritis. OMERACT 8 PsA Module Report. | Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, FitzGerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Sorian ER, Zochling J. | J Rheumatol 2007;34:1167-1170. | |||
| 2007 | Improved survival in psoriatic arthritis (PsA) with calendar time. | Ali Y, Tom BDM, Schentag CT, Farewell VT, Gladman DD. | Arthritis Rheum 2007;56:2708-2714. | |||
| 2007 | Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. | Najar HN and DUTZ, JP, | Eur J Immunol. 2007 Aug;37(8):2242-56 | |||
| 2007 | Treatment ofAtypical Nevi with Imiquimod 5% Cream, | Somani N, Martinka M, Crawford RI, DUTZ J , Rivers JK, | Arch Dermatol. 2007.Mar;143(3):379-85. | |||
| 2007 | Psoriasis and Pustular Dermatitis Triggered by Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatologic Conditions, | de Gannes GC, Ghoreishi M, Pope J; Russell A; Bell D; Adams S;Shojania K; Martinka M, DUTZ JP, | Arch Dermatol. 2007 Feb;143(2):223-31. | |||
| 2007 | IL-15 and psoriasis: Another genetic link to Th17? (commentary) | Elder JT: | Journal of Investigative Dermatology 127:2495-97, 2007. | |||
| 2007 | Antigliadin antibodies in patients with psoriasis. | Kia K, Nair R, Ike R, Hiremagalore R, Elder J, Ellis C: | American Journal of Clinical Dermatology 8:301-5, 2007 | |||
| 2007 | Psoriatic Arthritis: From Skin to Bone. Nature Clinical Practice | Ritchlin, CT. | Rheum. 2007;3(12): 698-706 PMID. 18609740. | |||
| 2007 | Psoriasis: epidemiology. | Gudjonsson JE, Elder JT | Clinics in Dermatology 25:535-46, 2007. | |||
| 2007 | Sensitivity of the Classification of psoriatic arthritis (CASPAR) Criteria in early psoriatic arthritis. | Chandran V, Schentag CT, Gladman DD. | Arthritis Rheum (Arthritis Care & Research) 2007;57:1560-1563. | |||
| 2007 | Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. | Chandran V, O'shea FD, Schentag CT, Inman RD, Gladman DD. | J Rheumatol 2007; 34:2463-2465. | |||
| 2007 | Grappa 2007: Prologue. | Gladman DD. | J Rheumatol 2008;35:1420-1422. | |||
| 2007 | Psoriatic Arthritis Screening Tools: A Report from the GRAPPA 2007 Annual Meeting. | Qureshi AA, Dominguez P, Callis Duffin K, Gladman DD, Helliwell P, Mease PJ, Husni ME. | J Rheumatol 2008;35:1423-1425. | |||
| 2007 | Genetics of Psoriasis and Psoriatic Arthritis: Update and Future Direction (GRAPPA 2007). | Callis Duffin K, Chandran V, Gladman DD, Krueger GG, Elder JT, Rahman P. | J Rheumatol 2008;35:1449-1453. | |||
| 2007 | Clinical and Genetic Registries: A Report of the GRAPPA 2007 Meeting. | Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Ståhle M. | J Rheumatol 2008;35:1458-1463. | |||
| 2007 | Familial aggregation of psoriatic arthritis (PsA): preliminary analysis of 100 consecutive families of patientse with PsA. | Chandran V, Pellett F, Schentag C, Gladman D. | J Rheumatol 2007;34:1596. | |||
| 2007 | A variant of the IL4R-I50V SNP is associated with greater burden of erosive joint disease in psoriatic arthritis. | Rahman P, Snelgrove T, Siannis F, Peddle L, Schentag C, Farewell V, Gladman D. | Ann Rheum Dis 2007;66(suppl II):97. | |||
| 2007 | Relationship between C-reactive protein concentration and joint damage in psoriatic arthritis (PSA): Subanalysis of placebo-and adalimumab-treated patients in ADEPT. | Gladman D, Mease P, Choy E, Sasso E. | Ann Rheum Dis 2007;66(suppl II):98. | |||
| 2007 | Familial Aggregation of psoriatic arthritis (PsA): preliminary analysis of 100 consecutive families of patients with PsA. | Chandran V, Pellett FJ, Schentag CT, Gladman DD. | Ann Rheum Dis 2007;66(suppl II):415. | |||
| 2007 | CASPAR criteria are sensitive in early psoriatic arthritis (PSA) and are accurate when applied to patients attending a family practice clinic. | Chandran V, Schentag CT, Gladman DD. | Ann Rheum Dis 2007;66(suppl II):415. | |||
| 2007 | Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from PsA study M02-537. | Mease P, Genovese M, Ritchlin CT, van den Bosch F, Wellborne F, Birbara C, Thomson G, Perdok R, Medich J, Wong R, Gladman D. | Ann Rheum Dis 2007;66(suppl II):419. | |||
| 2007 | Association of Interleukin-23R Variants with Psoriatic Arthritis. | Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. | Arthritis Rheum 2007; 56 (Suppl 9):S244. | |||
| 2007 | Analysis of Risk Factors for Radiographic Progression in Psoriatic Arthritis (PsA): Subanalysis of ADEPT. | Gladman D, Mease PJ, Choy EHS, Ritchlin CT, Perdok RJ, Sasso EH. | Arthritis Rheum 2007;56(suppl 9):S257. | |||
| 2007 | Patient and Physician Perception of Disease in Psoriatic Arthritsi (PsA). A Multicentre GRAPPA and OMERACT Study. | Cauli A, Gladman DD, Mathieu A, Olivieri I, Ujfalussy I, Scarpa R, Tak PP, Marchesoni A, Taylor W, Spadaro A, Fernandez-Sueiro JL, Salvarani C, Helliwell P, Lubrano E, Kalden J, Sueli C, Flynn JA, Porru G, Hewitt G, D’Angelo S, Schentag C, van Kuijk A, Vacca A, Peluso R, Catanoso M, Parsons WJ, Porcedda E, Gruenke M, Porceddu R, Mease P, GRAPPA study group. | Arthritis Rheum 2007; 56 (Suppl 9):S264. | |||
| 2007 | Radiographic Spinal Damage and Spinal Mobility Correlate Poorly in Psoriatic Spondylitis (Ps-Sp). | Chandran V, O'Shea FD, Schentag CT, Salonen D, Inman RD, Gladman DD. | Arthritis Rheum 2007;56 (Suppl 9): S483. | |||
| #VALUE! | Development and Validation of a Screening Questionnaire for Psoriatic Arthriits. | Gladman DD, Schentag CT, Tom B, Chandran V, Farewell VT. | Arthritis Rheum 2007;56 (Suppl 9): S798. | |||
| 2007 | International Multi-centre Psoriasis and psoriatic Arthritis Reliability Trial (GRAPPA-IMPART): Assessment of skin, joints, nails and dactylitis. | Chandran V, Cook R, Helliwell P, Kavanaugh A, McHugh N, Mease P, Olivieri O, Rahman P, Salvarani C, Toloza S, Zhou Q, Gladman DD. | Arthritis Rheum 2007;56 (Suppl 9): S798. | |||
| 2007 | Recurrence Risk of Psoriatic Arthritis (PsA) and Psoriasis (Ps) in Relatives of Patients with PsA. | Chandran V, Pellett FJ, Shanmugarajah S, Schentag CT, Brockbank J, Toloza S, Rahman P, Gladman DD. | Arthritis Rheum 2007;56 (Suppl 9): S798. | |||
| 2007 | Can a Patient Self-Reported Active Joint Count Replace a Physician’s Examination of the Joints for Inflammatory Activity? | Schentag CT, Chaudhry S, Gladman DD. | Arthritis Rheum 2007;56 (Suppl 9): S827. | |||
| 2007 | A New, Human, TNF-alpha Antibody Administered As A Monthly Subcutaneous Injection In Psoriatic Arthritis: 24-week Efficacy And Safety Results Of The Randomized, Placebo-Controlled GO-REVEAL Study. | Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gómez-Reino JJ, Papp K, Livingston J, Mudivarthy S, Mack ME, Beutler A. Golimumab, | Arthritis Rheum 2007:56:4308. | |||
| 2007 | Effectiveness of psoriasis treatments: a patients’ perspective. | Tejasvi T, Nair RP, Stuart PE, Voorhees JJ, Elder JT: | J Invest Dermatology 127 (suppl): 357, 2007 | |||
| 2007 | Fine mapping of psoriasis susceptibility locus PSORS2 on chromosome17q. | Nair RP, Stuart PE, Qin AZ, Abecasis GR, Jenisch S, Weichenthal M, Lim HW, Christophers E, Voorhees JJ, Elder JT: | J Invest Dermatology 126 (suppl): 533, 2007. | |||
| 2007 | Evidence for altered Wnt signaling in psoriatic skin. | Gudjonsson JE, Aphale A, Voorhees JJ, Elder JT: | J Invest Dermatology 126 (suppl): 593, 2007. | |||
| 2007 | Lack of evidence for activation of the Hedgehog pathway in psoriasis. | Aphale A, Gudjonsson JE, Grachtchouk M, Johnson T, Voorhees JJ, Dlugosz A, Elder JT: | J Invest Dermatology 126 (suppl): 594, 2007. | |||
| 2007 | Inducible expression of amphiregulin-specific small hairpin RNA blocks autocrine proliferation of human keratinocytes. | Stoll SW, Johnson JL, Elder JT: | J Invest Dermatology 126 (suppl): 608, 2007. | |||
| 2007 | Adipokines in the pathogenesis of psoriasis. | Johnston A, Gudjonsson JE, Signarsdottir AA, Gunnarsson SI, Arnadottir S, Steinsson JT, Elder JT, Valdimarsson H: | J Invest Dermatology 126 (suppl): 696, 2007. | |||
| 2007 | Transgenic expression of S100A2 in hairless mouse skin: Lack of effect on cutaneous responses to solar-simulated radiation. | Li Y, Gudjonsson JE, Elder JT: | J Invest Dermatology 126 (suppl): 851, 2007 | |||
| 2007 | A role for adipokines in the pathogenesis of psoriasis. | Johnston A, Gudjonsson JE, Sigmarsdottir AA, Gunnarsson, SI Arnadottir S, Davidsson S, Elder, JT, Valdimarsson H: | Scand J Immunol 65 (6): 602-603 (2007). | |||
| 2007 | Differences in the expression of HLA class I molecules in uninvolved and involved psoriatic skin. | Gudjonsson J, Tejasvi T, Aphale A, Stoll S, Nair R, Voorhees, J, Elder JT: | J Invest Dermatol 127 suppl 2, S72 (2007). | |||
| 2007 | Risk of myocardial infarction in patients with psoriatic disease, | H K. Choi, M Rahman, MS, JA. Kopec, JEsdaile, JP DUTZ, D Lacaille, | American College of Rheumatology Scientific Meeting Nov 6-11, 2007, Boston MA. | |||
| 2007 | Phenotype of dendritic cells and cytokine response to topical CpG adjuvant, DC2007, "Dendritic Cell Vaccination and other Strategies to tip the Balance of the Immune System", | Najar H, and DUTZ, JP, | July 16-18, 2007, Bamberg, Germany. | |||
| 2007 | Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. | Weichenthal M Nair RP, Ruether A, Stuart PE, Schreiber S, Christophers E, Voorhees J, Elder JT, Jenisch S: | J Invest Dermatol 127 suppl 2, S86 (2007). | |||
| 2008 | From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis | Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. | . J Am Acad Dermatol 2008;58:94-105. | |||
| 2008 | Malignancy in psoriatic arthritis. | Rohekar S, Tom BD, Hassa A, Schentag C, Farewell VT, Gladman DD. | Arthritis Rheum 2008;58:82-87. | |||
| 2008 | Reappraisal of the Effectiveness of Methotrexate in Psoriatic Arthritis: Results from a Longitudinal Observational Cohort. | Chandran V, Schentag CT, Gladman DD. | J Rheumatol 2008;35:469-471. | |||
| 2008 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. | Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ et al. | J Am Acad Dermatol 2008;58:1031-1042. | |||
| 2008 | Two-Year Efficacy and Safety of Infliximab Treatment in Patients with Active Psoriatic Arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). | Antoni CE, Kavanaugh A, van der HD, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. | J Rheumatol 2008;35:869-876. | |||
| 2008 | A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. | Rahman P, Snelgrove T, Peddle L, Siannis F, Farewell V, Schentag C, Gladman D. | Arthritis Rheum 2008;58:2207-2208. | |||
| 2008 | Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation. | Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, Steinsson JT, Elder JT, Valdimarsson H: | British Journal of Dermatology . 159:342-350, 2008. PMCID: PMC2757771 | |||
| 2008 | Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. | Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, Schreiber S, Kabelitz D, Lim HW, Voorhees JJ, Christophers E, Elder JT, Weichenthal M: | Journal of Investigative Dermatology 128:1653-61, 2008. PMCID: PMC2739284 | |||
| 2008 | Altered bone remodeling in psoriatic arthritis. | Mensah K, Schwarz E, Ritchlin CT. | Current Rheumatology Reports 2008; 10 (4): 311-317. Ann PMC2656567. | |||
| 2008 | The Effect of Etanercept Therapy on Clinical Outcome, Osteoclast Precursor Frequency and Bone Marrow Edema in Patients with Psoriatic Arthritis. | Anandarajah, A, Schwarz EM, Totteman S, Haas-Smith, SA, Ritchlin CT. | Ann Rheum Dis. 2008:67(3):296-301. PMID 17967829. | |||
| 2008 | Topical CpG enhances the response of murine malignant melanoma to dacarbazine, | Najar HN and DUTZ, JP, | J Invest Dermatol, 2008. Sep;128(9):2204-10. Epub 2008 Mar 27. | |||
| 2008 | 56th annual Montagna Symposium on the Biology of Skin: Epidermal T-cell interactions--clinicopathological and basic mechanisms. | Cooper KD, Sontheimer RD, DUTZ J, Hwang ST, Nickoloff BJ, Shimada S, Kulesz-Martin M, Bickenbach JR. | J Invest Dermatol. 2008 Jun;128(6):1351-3. | |||
| 2008 | Sensitivity and specificity of the CASPAR Criteria for Psoriatic Arthritis when applied to patients attending a Family Medicine Clinic. | Chandran V, Schentag CT, Gladman DD. | J Rheumatol 2008;35:2069-2070. | |||
| 2008 | GRAPPA at the European League Against Rheumatism (EULAR) 2008. | Gladman DD, Helliwell PS, Mease PJ. | J Rheumatol 2009;36:656-658. | |||
| 2008 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis | Gladman DD. | (GRAPPA) 2008. J Rheumatol 2010;37:446-447. | |||
| 2008 | Imaging in psoriasis and psoriatic arthritis. | Coates LC, McGonagle DM, Hodgson R, Gisondi Paolo, Kavanaugh AF, Qureshi AA, FitzGerald O, Mease PJ, Garg Am, Rosen CF, Ridley D, Gladman DD, Krueger GG, Ritchlin CT, Helliwell PS. | GRAPPA 2008. J Rheumatol 2010;37:448-452. | |||
| 2008 | Biomarkers in psoriasis and psoriatic arthritis: | Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Krueger GG, Kavanaugh AF, Fitzgerald O: | GRAPPA 2008. J Rheumatol 2010, 37(2):462-467. PMID. 20147482 | |||
| 2008 | Composite measures in psoriatic arthritis. | Gladman DD, Landewé R, McHigh NJ, FitzGerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A. | GRAPPA 2008. J Rheumatol 2010;37:453-456. | |||
| 2008 | Biomarkers in psoriasis and psoriatic arthritis. | Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Kreuger GG, Kavanaugh AF, FitzGerald O. | GRAPPA 2008. J Rheumatol 2010;37:462-467. | |||
| 2008 | Induction of memory IL-17+ T cell trafficking and expansion by interferon-gamma: mechanism and pathological relevance in psoriasis. | Bruce AT, Kryczek I, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Zou W, Elder JT: | J Invest Dermatol 128, suppl 1, A114, 2008. | |||
| 2008 | Initial pharmacogenomic assessment of TNF-alpha and TRAF1 ploymorphisms in psoriasis: response to TNF blockers and other systemic therapies. | Tejasvi T, Stuart PE, Nair RP, Voorhees JJ, Elder JT: | J Invest Dermatol 128, suppl 1, A442, 2008. | |||
| 2008 | Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. | Nair RP, Stuart PE, Kullavanijaya P, Tejasvi T, Voorhees JJ, Elder JT: | J Invest Dermatol 128, suppl 1, A678, 2008. | |||
| 2008 | Genome-wide association scan reveals novel psoriasis susceptibility loci. | Elder JT, Callis Duffin K, Helms C, Stuart PE, Ding J, Goldgar D, Tejasvi T, Gudjonsson JE, Liao W, Menter A, Voorhees JJ, Abecasis GR, Nair RP, Bowcock AM, Krueger GG: | J Invest Dermatol 128, suppl 1, A747, 2008. | |||
| 2008 | Global gene expression analysis reveals evidence for abnormal lipid biosynthesis in uninvolved psoriatic skin. | Gudjonsson JE, Ding J, Nair RP, Stuart PE, Aphale A, Tejasvi T, Voorhees JJ, Abecasis GR, Elder JT: | J Invest Dermatol 128, suppl 1, A768, 2008. | |||
| 2008 | Early psoriatic arhtirtis: establishing a cohort of patients with psoriasis uncomplicated by arthritis. | Chandran V, Shanmugarajah S, Pellettt F, Toloza S, Schentag C, Rosen C, Gladman D. | J Rheumatol 2008;35:1172. | |||
| 2008 | Effectiveness of adalimumab (Humira) in clinical practice. Results for the ACCLAIM study in patients with psoriatic arthritis. | Gladman DD, Wong RL, Guerette G. | J Rheumatol 2008;35:1185 | |||
| 2008 | A Pilot study on Biomarkers that differentiate Psoriatic Arthritis from Psoriasis alone. | Chandran V, Edwin J, Pellett F, Shanmugarajah S, Schentag CT, Rosen C, Gladman D. | Arthritis Rheum 2008;58:3997. | |||
| 2008 | Probands underestimate the prevalence of psoriatic arthritis in their relatives. | Chandran V, Ueng J, Shanmugarajah S, Pellett F, Schentag C, Rosen C, Gladman D. | J Rheumatol 2008;35:1209. | |||
| 2008 | Diagnosis and assessment of psoriatic arthritis. | Gladman DD. | Ann Rheum Dis 2008;67(Suppl II):43. | |||
| 2008 | Golimumab, a new human TNG alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients : 52 week efficacy and safety results of the randomized placebo-controlled Go-Reveal study. | Kavanaugh A, Mease P, Krueger GG, Gladman D, Gomez-Reino JJ, Papp K, Murphy F, Antoni C, Livingston J, Mudivarthy S, Mack M, Beutler A, McInnes I. | Ann Rheum Dis 2008; 67(Suppl II):99. | |||
| 2008 | Adalimumab (Humira) sustains inhibition of joint damage formore than 2 years in patients with psoriatic arthritis (PsA). | Mease PJ, Ory P, Sharp JT, Medich J, Perdok R, Ritchlin CT, Gladman DD. | Ann Rheum Dis 2008; 67(Suppl II):99. | |||
| 2008 | Risk factors for radiographic progression in psoriatic arthritis treated with adalimumab (Humira) or placebo : subanalysis of ADEPT. | Gladman DD, Mease PJ, Choy EHS, Ritchlin CT, Perdock RJ Sasso EH. | Ann Rheum Dis 2008; 67(Suppl II):100. | |||
| 2008 | PASI 50 response is a sensitive indicator of reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira): subamalysis of ADEPT. | Choy EHS, Gladman DD, Mease PJ, Ritchlin CT, Perdock RJ, Sasso EH. | Ann Rheum Dis 2008; 67(Suppl II):524. | |||
| 2008 | Golimumab, a new human TNF-alpha antibody administered every 4 weeks as a subcutaneous in jection in psoriatic arthirtis: nail enthesitis, and dactylitis response in the randomized placebo-controlled Go-Reveal study. | Gladman D, Kavanaugh A, McInnes I, Mease P, Gomez-Reino JJ, Papp K, Livingston J, Mudivarthy S, Mack ME, Beutler A, Krueger GG. | Ann Rheum Dis 2008; 67(Suppl II):526. | |||
| 2008 | Response criteria for psoraitic arthritis I: derivation of models for response. | Gladman DD, Tom BD, Mease PJ, Farewell VT | Ann Rheum Dis 2008; 67(Suppl II):526. | |||
| 2008 | Response criteria for psoraitic arthritis II: Developing and comparing response criteria for PsA. | Gladman DD, Tom BD, Mease PJ, Farewell VT. | Ann Rheum Dis 2008; 67(Suppl II):526. | |||
| 2008 | Golimumab, a new human TNF-alpha antibody administered every 4 weeks as a subcutaneous in jection in psoriatic arthirtis: response to pneumococcal vaccine in the randomized placebo-controlled Go-Reveal study. | McInnes I, Kavanaugh A, Krueger GG, Gladman D, Gomez-Reino JJ, Papp K, Livingston J, Hsu B, Mudvarthy S, Mack ME, Beutler A, Visvanathan S, Wagner CL, Mease P. | Ann Rheum Dis 2008; 67(Suppl II):529. | |||
| 2008 | Association of IRF5 polymorphisms in psoriatic arthritis. | Rahman P, Inman RD, Maksymowych WP, Peddle L, Uddin M, Pope A, Gladman DD. | Ann Rheum Dis 2008; 67(Suppl II):530. | |||
| 2008 | Association of IRF5 polymorphisms in psoriatic arthritis. | Rahman P, Inman RD, Makymowych WP, Roslin N, Peddle L, Uddin M, Popoe AM, Gladman DD. | Arthritis Rheum 2008:58(Suppl 9):S353 | |||
| 2008 | Identification of serum markers associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. | Visvanathan S, Gladman D, Brodmerkel C, Kavanaugh A, McInnes I, Mease P, Kreuger GG, Murphy F, Papp K, Gomez-Reino JJ, Mack M, Elashoff M, Livingston J, Beutler A, Wagner C. | Ann Rheum Dis 2008; 67(Suppl II):533. | |||
| 2008 | Golimumab significantly improves physical function, health related quality of life productivity and reduces time lost from work for caregivers in patients with active psoriatic arthritis. | Mease P, McInnes I, Krueger GG, Gladman D, Gomez-Reino JJ, Papp K, Livingston J, Mudivarthy S, Mack M, Beutler A, Parasuraman S, Buchanan J, Han C, Kavanaugh A. | Ann Rheum Dis 2008; 67(Suppl II):572. | |||
| 2008 | Reliability and validity of the work limitations questionnaire (WLQ) and impact of adalimumab (HUMIRA) on presenteeism for patients with psoriatic arthritis (PsA). | Gladman DD, Sampalis JS, Martel MJ, Gooch KL, Wong R, Guerette B. | Arthritis Rheum 2008;58(Suppl 9):S202. | |||
| 2008 | Response Criteria for Psoriatic Arthritis II: Developing and comparing response criteria for PsA. | Gladman DD, Tom B, Mease P, Farewell VT. | Arthritis Rheum 2008;58(Suppl 9):S363. | |||
| 2008 | Treatment recommendations for psoriatic arthritis. | Ritchlin CT, Kavanaugh A, Gladman D. Mease P, Beuhncke WH, deVlam K, Fiorentino D, FitzGerald O, Gottlieb A, McHugh N, Nash P, Qureshi A, Soriano E, Taylor W. | Arthritis Rheum 2008:58(Suppl 9):S363. | |||
| 2008 | A Pharmacogenetic Study On The Efficacy Of Methotrexate (MTX) In Psoriatic Arthritis (PsA). | Chandran V, Siannis F, Schentag CT, Peddle L, Pellett FJ, Farewell V, Rahman P, Gladman DD. | Arthritis Rheum 2008:58(Suppl 9):S364. | |||
| 2008 | Clinical Predictors for Psoriatic Arthritis (PsA) in Patients with Psoriasis. | Chandran V, Toloza S, Shanmugarajah S, Pellett FJ, Schentag CT, Rosen C, Gladman DD. | Arthritis Rheum 2008;58(Supple 9):S364. | |||
| 2008 | Risk Factors for the Development of Spondylitis in Patients with Psoriatic Arthritis (PsA). | Chandran V, Tolusso DC, Schentag CT, Cook RJ, Gladman DD. | Arthritis Rheum 2008:58(Suppl 9):S364. | |||
| 2008 | Defining psoriatic spondylitis (PsSp). | Chandran V, Tolusso DC, Schentag CT, Cook RJ, Gladman DD. | Arthritis Rheum 2008:58(Suppl 9):S365. | |||
| 2008 | Progression of Spondylitis in Patients with Psoriatic Arthritis (PsA). | Chandran V, Barrett J, Schentag CT, Farewell V, Gladman DD. | Arthritis Rheum 2008:58(Suppl 9):S365. | |||
| 2008 | Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis (PsA). | Toloza S, Chandran V, Schentag C, Gladman DD. | Arthritis Rheum 2008;58(Suppl 9):S366. | |||
| 2008 | Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients : 52 week efficacy and safety results of the randomized placebo-controlled Go-Reveal study. | Kavanaugh A, Mease P, Krueger GG, Gladman D, Gomez-Reino JJ, Papp K, Murphy F, Antoni C, Livingston J, Mudivarthy S, Mack M, Beutler A, McInnes I. | Arthritis Rheum 2008;58(Suppl 9):S414. | |||
| 2008 | Golimumab significantly improves physical function, health related quality of life productivity and reduces time lost from work for caregivers in patients with active psoriatic arthritis. | Mease P, McInnes I, Krueger GG, Gladman D, Gomez-Reino JJ, Papp K, Livingston J, Mudivarthy S, Mack M, Beutler A, Parasuraman S, Buchanan J, Han C, Kavanaugh A. | Arthritis Rheum 2008;58(Suppl 9):S574. | |||
| 2008 | Golimumab, a new human TNF-alpha antibody administered every 4 weeks as a subcutaneous in jection in psoriatic arthirtis: nail enthesitis, and dactylitis response in the randomized placebo-controlled Go-Reveal study. | Gladman D, Kavanaugh A, McInnes I, Mease P, Gomez-Reino JJ, Papp K, Livingston J, Mudivarthy S, Mack ME, Beutler A, Krueger GG. | Arthritis Rheum 2008;58(Suppl 9):S575. | |||
| 2008 | Improvement in psoriasis is associated with long-term inhibition of radiographic progression in patients with psoriatic arthritis receiving adalimumab (HUMIRA). | Choy E, Gladman DD, Mease P, Ritchlin C, Olds M, Wong R, Wang S, Medich J. | Arthritis Rheum 2008;58(Suppl 9):S575. | |||
| 2008 | Predictors of response to intra-articular steroid injection in psoriatic arthritis. | Eder L, Chandran V, Ueng J, Bhella S, Schentag C, Lee KA, Cook RJ, Gladman DD. | Arthritis Rheum 2008;58:3991. | |||
| 2008 | Frequency and Predictors of Minimal Disease Activity in an Observational PsA Cohort. | Coates LC, Schentag C, Lee KA, Chandran V, Cook R, Gladman DD. | Arthritis Rheum 2008;58:3997. | |||
| 2009 | Occurrence and correlates of fatigue in psoriatic arthritis (PsA). | Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. | Ann Rheum Dis 2009;68:1553-1558. | |||
| 2009 | Treatment Recommendations for Psoriatic Arthritis. | Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Boehncke WH, de Vlam K, Fiorentino D, FitzGerald O, Gottlieb AB, McHugh N, Nash PT, Qureshi AA, Soriano ER, Taylor WJ. | Ann Rheum Dis 2009;68:1387-1394. | |||
| 2009 | Genome-wide scan of psoriasis reveals association with IL-23 and NF-kappaB pathways. | Nair RP, Callis Duffin K, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson J, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok P, Menter A, Lathrop GM, Wise C, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR: | Nature Genet 41(2):199-204, 2009. PMCID: PMC2745122. | |||
| 2009 | cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. | Wang JC, Kobie JJ, Zhang L, Cochran M, Mosmann TR, Ritchlin CT, Quataert SA. | J Immunol Methods. 2009 Feb 28; 341(1-2):106-116. PMID 19049808. | |||
| 2009 | The quest for a biomarker of circulating osteoclast precursors. | Ritchlin C: | Arthritis Res Ther2009, 11(3):113. PMID. 19591635. | |||
| 2009 | The diagnosis and treatment of early psoriatic arthritis. | Anandarajah A., Ritchlin CT. | Nat Rev Rheum. 2009 11:634-641. PMID. 19806150. | |||
| 2009 | Deletion of the late cornified envelope (LCE) 3B and 3C genes as a susceptibility factor for psoriasis. | de Cid R, Riveira-Munoz E, Zeeuwen PLJM, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair RP, Helms C, Escaramís G, Ballana E, Martín-Ezquerra G, den Heijer M, Kamsteeg M, Joosten I, Eichler EE, Lázaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JAL, Kwok P, Bowcock A, Schalkwijk J, Estivill X: | Nature Genetics 41(2):211-5, 2009. PMCID: PMC3128734. | |||
| 2009 | Genome-wide association scan reveals new insights into the pathogenesis of psoriasis. | Elder JT: | Genes and Immunity 10:201-209, 2009. PMCID: PMC2683580. | |||
| 2009 | Psoriasis bench to bedside – genetics meets immunology. | Nair RP, Ding J, Callis Duffin K, Helms C, Voorhees JJ, Krueger GG, Bowcock AM, Abecasis GR, Elder JT: | Archives of Dermatology 145:462-464, 2009. PMCID: PMC2739283. | |||
| 2009 | Ustekinumab: A new option in psoriasis therapy. | Chien A, Elder JT, Ellis CN | Drugs 69(9):1141-52, 2009. | |||
| 2009 | Association of Interleukin-23R Variants with Psoriatic Arthritis | Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. | J Rheumatol 2009;36:137-140. | |||
| 2009 | Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. | Gudjonsson JE, Ding J, Li X, Nair R, Stuart P, Tejasvi T, Aphale A, Gumucio DL, Voorhees JJ, Abecasis G, Elder JT: | Journal of Investigative Dermatology 129(12):2795-2804, 2009. PMCID: PMC2783967. | |||
| 2009 | Multiple loci within the major histocompatibility complex confer risk of psoriasis. | Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair, Stuart P, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar DE: | PLoS Genet. 2009 Aug;5(8):e1000606. PMCID: PMC2718700. | |||
| 2009 | Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. | Nair RP, Stuart PE, Kullavanijaya P, Kullavanijaya P, Tejasvi T, Voorhees JJ, Elder JT: | Archives of Dermatological Research 302:139-43, 2009. PMCID: PMC2897822. | |||
| 2009 | Retinoic acid 4-hydroxylase infucibility and clinical response to isotretinoin in patients with acne. | Wang F, Kwak HS, Elbuluk N, Kaczmarek AL, Hamilton T, Voorhees JJ, Fisher GJ, Kang S: | Journal of American Academy of Dermatology 61(2):252-8, 2009. PMCID: PMC3103843. | |||
| 2009 | The Collaborative Association Study of Psoriasis. Genome-wide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways. | Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng B, Ruether A, Weichentha M, Gladman D, Rahman P, Schrodi SJ, S Prahalad D, Guthery SL, Fisher J, Liao W, Kwok P, Menter A, Lathrop GM, Wise C, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, BowcockAM, Abecasis GR. | Nature Genetics 2009;41:199-204. | |||
| 2009 | Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS). | Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen CF et al. | Ann Rheum Dis 2009;68:497-501. | |||
| 2009 | Familial aggregation of psoriatic arthritis | Chandran V, Schentag CT, Brockbank J, Pellett FJ, Shanmugrajah, S, Toloza SMA, Rahman P, Gladman DD. | Ann Rheum Dis 2009;68:664-667. | |||
| 2009 | Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). | Mease PJ, Ory P, Sharp J, Ritchlin CT, van den Bosch F, Wellborne F, Birbara C, Thomson G, Perdok R, Medich J, Wong R, Gladman DD. | Ann Rheum Dis 2009;68:702-709. | |||
| 2009 | Cardiovascular morbidity in psoriatic arthritis (PsA). | Gladman DD, Ang M, Su L, Tom BDM, Schentag CT, Farewell VT. | Ann Rheum Dis 2009;68:1131-1135. | |||
| 2009 | Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomised, placebo-controlled, GO-REVEAL study. | Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Livingston J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. | Arthritis Rheum 2009;60:976-986. | |||
| 2009 | From ankylosis to pencil-in-cup deformity in psoriatic arthritis: a case report. | Eder L, Chandran V, Gladman DD. | Clin Exp Rheumatol 2009;27:661-663. | |||
| 2009 | International Multi-centre Psoriasis and Psoriatic Arthritis Reliability Trial (GRAPPA-IMPART): Assessment of Skin, Joints, Nails and Dactylitis. | Chandran V, Gottlieb AB, Cook RJ, Callis Duffin K, Garg A, Helliwell PS, Kavanaugh A, Kreuger GG, Langley R, Lynde C, McHugh N, Mease PJ, Olivieri I, Rahman P, Rosen CF, Salvarani C, Thaci D, Toloza SMA, Wong M, Zhou Q, Gladman DD. | Arthritis Rheum (Arthritis Care & Res) 2009;61:1235-1242 | |||
| 2009 | T cell mediated injury to keratinocytes: Insights from animal models of the lichenoid tissue reaction, | DUTZ, JP, | J Invest Dermatol. 2009.Feb;129(2):309-14. | |||
| 2009 | Axial Psoriatic Arthritis: Update on a Longterm Prospective Study. | Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. | J Rheumatol 2009;36:2744-2750. | |||
| 2009 | Significance of Clinical Evaluation of the Metacarpophalangeal Joint in Relation to Synovial/Bone Pathology in Rheumatoid and Psoriatic Arthritis Detected by Magnetic Resonance Imaging. | Stone MA, White LM, Gladman DD, Inman R, Chaya S, Lax M, Salonen, Weber DA, Guthrie JA, Pomeroy E, Podbielski D, Keystone EC. | J Rheumatol 2009;36:2751-2757. | |||
| 2009 | Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). | Mease PJ, Gladman DD. | J Rheumatol 2011;38:522-525. | |||
| 2009 | Toronto Psoriatic Arthritis Screening (ToPAS) Questionnaire: A Report from the GRAPPA 2009 Annual Meeting. | Chandran V, Gladman DD. | J Rheumatol 2011;38:546-547. | |||
| 2009 | Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting. | Boehncke WH, Gladman DD, Chandran V. | J Rheumatol 2011;38:567-571. | |||
| 2009 | High-resolution association mapping in the MHC region identifies multiple independent loci for psoriatic arthritis. | Rahman P, Roslin N, Pellett F, Paterson A, Beyene J, Lemire M, Peddle M, Pope A, Greenwood C, Gladman D. | Arthritis Rheum 2009;60(Suppl 9):S536. | |||
| 2009 | Microarray Analyses of Peripheral Blood Cells Identifies Gene Expression Profile That Differentiates Psoriatic Arthritis (PsA) from Psoriasis and Controls. | Gladman D, Pollock R, Virtanen C, Pellett F, Shanmugarajah S, Rosen C, Chandran V. | Arthritis Rheum 2009;60(Suppl 9):S537. | |||
| 2009 | Predictors of response to intra-articular steroid injections in psoriatic arthritis. | Eder L, Chandran V, Bhella S, Schentag CT, Lee K-A, Cook RJ, Gladman DD. | J Rheumatol 2009;36:2589 | |||
| 2009 | Frequency and predictors of minimal disease activity in an observational PsA cohort. | Coates LC, Schentag CT, Lee K, Chandran V, Cook RJ, Gladman DD. | Ann Rheum Dis 2009; 68(Suppl3):137 | |||
| 2009 | Adalimumb in psoriatic arthritis: Improvement in psoriasis is associated with long-term inhibition of radiographic progression. | Choy EHS, Gladman DD, Mease PJ, Ritchlin CT, Olds M, Wong RL, Wang S, Medich J. | J Rheumatolg 2009;36:2571. | |||
| 2009 | Evaluation of response using the psoriatic arthritis joint activity index scoring tool in patients treated with adalimumab: post hoc analysis of the ACCLAIM study. | Gladman DD, Psaradellis F, Illouz O, Sampalis JS. | J Rheumatol 2009:36:2571. | |||
| 2009 | Impact of adalimumab on presenteeism for patients with psoriatic arthritis and reliability and validity of the work limitations questionnaire: Results of ACCLAIM. | Gladman DD, Sampalis JS, Martel MJ, Gooch KL, Wong RL, Guerette B. | J Rheumatol 2009;36:2595. | |||
| 2009 | Impact of adalimumab (HUMIRA) on work productivity in patients with psoriatic arthritis: results from ACCLAIM. | Gladman DD, Psaradellis F, Martel MJ, Illouz O, Guerette B, Sampalis JS. | J Rheumatol 2009;36:2595. | |||
| 2009 | Epidermal growth factors synergize with the psoriasis-associated inflammatory cytokines IL-1, IL-17 and IL-22 promoting keratinocyte antimicrobial peptide and chemokine expression. | Johnston A, Gudjonsson JE, Elder: | J Invest Dermatol 129, suppl 1, A132, 2009. | |||
| 2009 | IL17C is a pro-inflammatory cytokine up-regulated in lesional psoriatic skin induced by IL-17A and IL-22. | Riblett M. Johnston A, Bruce AT, Xing X, Voorhees JJ, Elder JT, Gudjonsson JE: | J Invest Dermatol 129, suppl 1, A137, 2009. | |||
| 2009 | profiling of recently-identified IL-1 family cytokines in psoriasis. | Xing X, Johnston A, Riblett M. Bruce AT, Shum M, Voorhees JJ, Elder JT, Gudjonsson JE: | J Invest Dermatol 129, suppl 1, A139, 2009. | |||
| 2009 | Polymorphisms in TNFAIP3 as a predictor of response to TNF blockage in psoriasis. | Tejasvi T, Stuart PE, Nair RP, Voorhees JJ, Elder JT: | J Invest Dermatol 129, suppl 1, A327, 2009. | |||
| 2009 | Analysis of the HLA-Cw1-B46 psoriasis risk haplotype reveals allelic herogeneity with HLA-Cw6. | Nair RP, Stuart PE, Hiremagalore R, Kullavanijaya P, Tejasvi T, Voorhees JJ, Elder JT: | J Invest Dermatol 129, suppl 1, A489, 2009. | |||
| 2009 | Multiple independent loci within the major histocompatibility complex confer risk of psoriasis. | Feng B, Soltani-Arabshi R, Bowcock AM, Nair RP, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Callis-Duffin KP, Goldgar DE, Krueger GG: | J Invest Dermatol 129, suppl 1, A510, 2009. | |||
| 2009 | Haplotype analysis implicates MICA*002 in susceptibility to psoriatic arthritis. | Nair RP, Stuart PE, Voorhees JJ, Elder JT: | J Invest Dermatol 129, suppl 1, A532, 2009. | |||
| 2009 | A genome-wide association study of gene expression in skin and psoriatic lesions. | Gudjonsson JE, Ding J, Nair RP, Liang L. Voorhees JJ, Abecasis GR, Elder JT: | J Invest Dermatol 129, suppl 1, A535, 2009. | |||
| 2009 | Inhibition of human keratinocyte growth by amphiregulin-specific shRNA cannot be reversed by EGFR ligands. | Stoll SW, Rittié L, Elder JT: | J Invest Dermatol 129, suppl 1, A573, 2009. | |||
| 2009 | Psoriasis lesions contain distinct populations of CD4+ and CD8+ T cells producing interferon gamma, interleukin-17, and interleukin-22. | Rubin CJ, Kryczek I, Gudjonsson JE, Johnston A, Zou W, Elder JT: | J Invest Dermatol 129, suppl 1, A697, 2009. | |||
| 2009 | REPArE (Rating evaluation in psoriatic arthritis with enbrel): Interim analysis of a Canadian Phase 4 post-marketing study of etanercept in psoriatic arthritis. | Gladman D, Bombardier C, Thorne C, Haraoui P, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M. | J Rheumatol 2009;36:2602. | |||
| 2009 | Soluble biomarkers differentiate psoriatic arthritis from psoriasis. | Chandran V, Edwin J, Shen H, Pellett F, Shanmugarajah S, Schentag CT, Rosen CF, Cook RJ, Gladman DD. | Ann Rheum Dis 2009;68(Suppl3):139. | |||
| 2009 | High-resolution association mapping in the MHC region identifies multiple independent loci for psoriatic arthritis. | Rahman P, Roslin N, Pellett F, Paterson A, Beyene J, Lemire M, Peddle M, Pope A, Greenwood C, Gladman D. | Ann Rheum Dis 2009;68(Suppl3):111. | |||
| 2009 | High-resolution association mapping in the MHC region identifies multiple independent loci for psoriatic arthritis. | Rahman P, Roslin N, Pellett F, Paterson A, Beyene J, Lemire M, Peddle M, Pope A, Greenwood C, Gladman D. | Arthritis Rheum 2009;60(Suppl 10):S536 | |||
| 2009 | Achieving minimal disease activity (MDZ) criteria decreases progression of joint damage in PsA. | Coates L, Schentag CT, Lee K, Chandran V, Cook RJ, Gladman DD. | Ann Rheum Dis 2009; 68(Suppl3):659. | |||
| 2009 | Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of the randomized, placebo-controlled GO-REVEAL study. | Kavanaugh A, Gladman D, Mease P, McInnes I, Beutler A, Zrubek J, Buchanan J, Parasuraman S, Mack M, Krueger GG, on behalf of GO-REVEAL Study Group. | Ann Rheum Dis 2009;68(Suppl3):652. | |||
| 2009 | Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. | Kavanaugh A, Mease P, Krueger GG, Gladman D, Zrubek J, Beutler A, Hsu B, Mudivarthy S, Mack M, McInnes I, on behalf of G0-REVEAL Study Group. | Ann Rheum Dis 2009 ;68(Suppl3):136. | |||
| 2009 | Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. | Kavanaugh A, Mease P, Krueger GG, Gladman D, Zrubek J, Beutler A, Hsu B, Mudivarthy S, Mack M, McInnes I, on behalf of G0-REVEAL Study Group. | Arthritis Rheum 2009;60(Suppl 10):S189. | |||
| 2009 | The Impact of Psoriatic Arthritis (PsA) According to the International Classification of Functioning, Health and Disability (ICF). | Taylor WJ, Gladman DD, Mease PJ, Adebajo A, Nash P, Feletar M. | Arthritis Rheum 2009;60(Suppl 10):S190. | |||
| 2009 | Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. | Chandran V, Fotios Siannis F, Rahman P, Schentag CT, Farewell V, Gladman DD. | Arthritis Rheum 2009;60(Suppl 10):S194. | |||
| 2009 | Comparison Between Inspire and Domjan Method for Measuring Lumbar Lateral Flexion in Patients of Psoriatic Arthritis (PsA) and Correlation with Radiographic Damage. | Wakhlu A, Phumethum V, Chandran V, Schentag CT, Shen H, Cook J, Gladman D. | Arthritis Rheum 2009;60(Suppl 10):S203. | |||
| 2009 | Abatacept in Psoriatic Arthritis: Results of a Phase II Study | Mease P, Genovese M, Ritchlin C, Wollenhaupt J, Tak PP, Kivitz A, Gladstein G, Bahary O, Kelly S, Teng J, Becker JC, Gladman D. | Arthritis Rheum 2009;60(Suppl 10):SS472. | |||
| 2009 | Golimumab Administered Subcutaneously Every 4 Weeks in Psoriatic Arthritis Patients: 52-Week Health-Related Quality of Life, Physical Function and Health Economic Results of the Randomized, Placebo-Controlled GO-REVEAL Study. | Kavanaugh A, Gladman D, Mease P, McInnes IB, Beutler A, Zrubek J, Buchanan J, Parasuraman S, Mack M, Krueger GG. | Arthritis Rheum 2009;60(Suppl 10):S472. | |||
| 2009 | Microarray Analyses of Peripheral Blood Cells Identifies Gene Expression Profile That Differentiates Psoriatic Arthritis (PsA) from Psoriasis and Controls. | Gladman D, Pollock R, Virtanen C, Pellett F, Shanmugarajah S, Rosen C, Chandran V. | Arthritis Rheum 2009;60(Suppl 10):S537. | |||
| 2009 | Biomarkers Predict Response to Anti-Tumour Necrosis Factor (TNF) Therapy in Psoriatic Arthritis (PsA). | Arthritis Rheum 2009;60(Suppl 10):S666. | ||||
| 2009 | Soluble Biomarkers in Psoriatic Disease: Differences Between Psoriasis and Psoriatic Arthritis. | Chandran V, Edwin J, Shen H, Pellett F, Shanmugarajah S, Schentag CT, Rosen CF, Cook RJ, Gladman DD. | Arthritis Rheum 2009;60(Suppl 10):S666. | |||
| 2009 | Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. | Kavanaugh A, van der Heijde D, Gladman D, Mease P, McInnes I, Krueger GG, Xu W, Rahman MU, Zrubek J, Baratelle A, Beutler A. | Arthritis Rheum 2009;60:3861. | |||
| 2010 | Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. | Menon K, Voorhees AS, Bebo BF Jr., Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE, and National Psoriasis Foundation. | J Amer Acad Dermatol 2010; 62:291-299. | |||
| 2010 | Molecular dissection of psoriasis: Integrating genetics and biology (Review). | Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Abecasis G, Voorhees JJ, Nair RP: | Journal of Investigative Dermatology 130(5):1213-26, 2010. | |||
| 2010 | Assessment of the psoriatic transcriptome in a large sample: Additional regulated genes and comparisons with in vitro models. | Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees JJ, Abecasis G, Elder JT: | Journal of Investigative Dermatology 130:1829-40, 2010. PMCID: PMC3128718. | |||
| 2010 | Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. | Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM: | Arthritis Rheum 2010, 62(4):1127-1137. PMC 2854832 (featured on cover). | |||
| 2010 | Evidence for altered Wnt signaling in psoriatic skin. | Gudjonsson JE, Johnston A, Stoll SW, Riblett M, Xing X, Kochkodan M, Ding J, Nair RP, Aphale A, Voorhees JJ, Elder JT: | Journal of Investigative Dermatology 130:1849-59, 2010. PMCID: PMC2886156. | |||
| 2010 | Comparative Analysis of Disease Activity Measures, Use of Biologic Agents, Body Mass Index, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large U.S. Disease Registry. | Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, Reed G, Chen R, Messing S, Kaukeinen K, Ritchlin, CT: | J Rheumatol 2010 37(12):2566-72. PMID 20843908. | |||
| 2010 | Comparison of MHC Class I risk haplotypes in Thai and Caucasian psoriatics reveals locus heterogeneity at PSORS1. | Stuart PE, Nair RP, Hiremagalore R, Kullavanijaya P, Kullavanijaya P, Tejasvi T, Lim HW, Voorhees JJ, Elder JT: | Tissue Antigens 76(5):387-97, 2010. PMCID: PMC2970686. | |||
| 2010 | What can psoriasis teach us about the genetic basis of CTCL? | Elder JT: | Clinical Lymphoma, Myeloma, and Leukemia 10 Suppl. 2, S70-S73, 2010. | |||
| 2010 | Genome-wide association analysis identifies three psoriasis susceptibility loci. | Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Mroweitz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, Gladman D, Elder JT: | Naure Genetics 42(11):1000-4, 2010. PMCID: PMC2965799. | |||
| 2010 | CD16 (FcRIII) as a potential marker of osteoclast precursors in psoriatic arthritis. | Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT: | Arthritis Res Ther2010, 12(1):R14.PMID 20102624. | |||
| 2010 | RANKL Induces Heterogeneous DC-STAMPlo and DC-STAMPhi Osteoclast Precursors of Which the DC-STAMPlo Precursors Are the Master Fusogens. | Mensah KA, Ritchlin CT, Schwarz EM. | J Cell Physiol2010;223: 76-83. PMC 2814997. | |||
| 2010 | Genome-wide association study reveals association of psoriasis with TRAF3IP2. | Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J, Li Y, Tejasvi T, Gudjonsson J, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman D, Gieger C, Wichmann HE, Karlsen TH, Kabelitz D, Abecasis GR, Elder JT Schreiber S, Weichenthal M, Franke M: | Nature Genetics 42(11):991-5, 2010. PMCID: PMC3136364. | |||
| 2010 | Association analyses identify six new psoriasis susceptibility loci in the Chinese population. | Sun LD, Wang ZX, Chen C, Zhang AP, Wang PG, Xu JH, Zhu QX, Zhou HS, Buchert E, Zhang FR, Pu XM, Yang XQ, Zhang JZ, Xu AE, Wu RN, Xu LM, Duan SH, Helms CA, Ren YQ, Zhang C, Shu-Zhang SM, Nair RP, Wang HY, Lin GS, Stuart PE, Fan X, Chen G, Tejasvi T, Li P, Zhu J, Li ZM, Ge HM, Weichenthal M, Ye WZ, Zhang C, Shen SK, Yang BQ, Sun YY, Li SS, Lin Y, Jiang JH, Li CT, Chen RX, Cheng J, Jiang X, Zhang P, Song WM, Tang J, Zhang HQ, Sun L, Cui J, Zhang LJ, Tang B, Huang B, Qin Q, Pei XP, Zhou AM, Shao L-M, Liu JL, Zhang FY, Du WD, Franke A, Bowcock AM, Elder JT, Liu JJ, Yang S, Zhang XJ: | Nature Genetics Nat Genet.42(11):1005-9, 2010. PMCID: PMC3140436. | |||
| 2010 | Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals. | Ding J, Gudjonsson JE, Liang L, Stuart PE, Li Y, Chen W, Weichenthal M, Ellinghaus E, Franke F, Cookson W, Nair RP, Elder JT Abecasis GR: | American Journal of Human Genetics 87(6):779-89, 2010. PMCID: PMC2997368. | |||
| 2010 | Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. | Chandran V, Tolusso DC, Schentag CT, Cook RJ, Gladman DD. | J Rheumatol 2010;37:809-815.. | |||
| 2010 | Aortitis and spondyloarthritis – an unusual presentation. A case report and review of the literature. | Eder L, Sadek M, McDonald-Blumer H, Gladman DD. | Semin Arthritis Rheum 2010;39:510-514. | |||
| 2010 | Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. | Gladman DD, Mease PJ, Choy EHS, Ritchlin CT, Perdok RJ, Sasso EH. | Arthritis Res Ther 2010, 12:R113. | |||
| 2010 | Time to and predictors of response to Tumour Necrosis Factor- α blockers in psoriatic arthritis – An analysis of a longitudinal observational cohort. | Eder L, Chandran V, Shen H, Schentag CT, Cook RJ, Gladman DD. | Rheumatology (Oxford) 2010;49:1361-1366. | |||
| 2010 | Predictors of response to intra-articular steroid injection in psoriatic arthritis. | Eder L, Chandran V, Ueng J, Bhella S, Lee K-A, Cook RJ, Gladman DD. | Rheumatology (Oxford) 2010;49:1367-1373. | |||
| 2010 | Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. | Chandran V, Siannis F, Rahman P, Pellett PJ, Farewell VT, Gladman DD. | . J Rheumatol 2010;37:1508-1512. | |||
| 2010 | Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. | Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, Rosen CF, Gladman DD. | Rheumatology (Oxford) 2010;49:1399-1405.. | |||
| 2010 | Frequency, predictors and prognosis of Minimal Disease Activity in an Observational PsA Cohort. | Coates LC, Lee KA, Chandran V, Cook R, Gladman DD. | Arthritis Care & Research 2010;62:970-976. | |||
| 2010 | Longitudinal Analysis of Fatigue in Psoriatic Arthritis (PsA). | Husted JA, Tom BDM, Farewell VT, Gladman DD. | J Rheumatol 2010;37:1878-1884. | |||
| 2010 | Impact of psoriatic arthritis according to the affected categories of the international classification of functioning disability and health (ICF). | Taylor WJ, Mease PJ, Adebajo A, Nash PJ, Feletar M, Gladman DD. | J Rheumatol Online 2010;37:1885-1891. | |||
| 2010 | Informing Response Criteria for Psoriatic Arthritis I: Discrimination models based on data from three anti-TNF randomized studies. | Gladman DD, Tom BDM, Mease PJ, Farewell VT. | J Rheumatol 2010;37:1892-1897. | |||
| 2010 | Cutaneous GVHD is associated with the expansion of tissue localised Th1 and not Th17 cells. | Broady R, Yu J, Chow V, Tantiworiwat A, Kang C, Berg K, Martinka M, Ghoreishi M, Dutz JP, Levings MK, | Blood. 2010 Dec 16;116(25):5748-51 | |||
| 2010 | Responses to Adalimumab in Patients With Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-Label Study. | Gladman DD, Sampalis JS, Illouz O, Guérette, B. | J Rheumatol 2010;37:1898-1906. | |||
| 2010 | Genome-wide association study reveals association of psoriasis with TRAF3IP2. | Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Ding J, Li Y, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman D, Gieger C, H. Erich Wichmann HE, Karlsen TH, Kabelitz D, Abecasis GR, Elder JT, Schreiber S, Weichenthal M, Franke A. | Nature Genetics 2010;42:991-995. | |||
| 2010 | Genome-wide association analysis identifies three psoriasis susceptibility loci. | Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudnonsson JE, Li Y, Wedinger S, Eberleing B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, Mrowietz U, Lim HW, Voorhess JJ, Abecasis GR, Weidchenthal M, Franke A, Rahman P, Gladman DD, Elder JT. | Nature Genetics 2010;42:1000-1004. | |||
| 2010 | Early-onset obesity and risk for psoriatic arthritis. | Gladman DD, Callen JP. | JAMA 2010; 304:787-788 (Editorial) | |||
| 2010 | Recognizing psoriatic arthritis. | Garg A, Gladman DD. | Journal of the Amer Acad Dermatol 2010;63:733-748. | |||
| 2010 | Is ASDAS better than BASDAI as a measure of disease activity in Axial Psoriatic Arthritis? | Eder L, Chandran V, Shen H, .Cook RJ, Gladman DD. | Ann Rheum Dis 2010.;69:2160-2164. | |||
| 2010 | Informing Response Criteria for Psoriatic Arthritis II: Further considerations and a proposal – the PsA Joint Activity Index (PsAJAI) | Gladman DD, Tom BDM, Mease PJ, Farewell VT. | J Rheumatol 2010.;37:2559-2565. | |||
| 2010 | Genetics of psoriasis and psoriatic arthritis: A report from the GRAPPA 2010 annual meeting (review). | Rahman P, Elder JT: | Journal of Rheumatology, submitted | |||
| 2010 | Golimumab, a new, human TNF alpha antibody, administered SC every 4 weeks in PsA patients: 104-week efficacy and safety results of the randomized placebo controlled GO-REVEAL study. | Gladman D, Kavanaugh A, Mease P, Krueger G, Zrubek J, Beutler A, Hsu B, Mdivarthy S, Mack M, Mcinnes I. | J Rheumatol 2010;37:1327 | |||
| 2010 | Prevalence of Vitamin D Insufficiency and Clinical Outcomes in Psoriatic Arthritis Patients. | Touma Z, Eder L, Chandran V, Rosen C, Schentag C, Cook R, Shen H, Gladman D. | J Rheumatol 2010;37:1347. | |||
| 2010 | Abatacept in patients with psoriatic arthritis: results of a phase II study. | Mease P, Genovese M, Ritchlin C, Wollenhaupt J, Tak PP, Kivitz A, Gladstein G, Bahary O, Kelly S, Teng J, Becker JC, Gladman D. | Ann Rheum Dis 2010;69(Suppl3):581 | |||
| 2010 | Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. | Kavanaugh A, van der Heijde D, Gladman D, Mease P, McInnes I, Krueger GG, Xu W, Rahman MU, Zrubek J, Baratelle A, Beutler A. | Ann Rheum Dis 2010;69(Suppl3):116 | |||
| 2010 | Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. | Gladman D, Kavanaugh A, van der Heijde D, Mease P, McInnes I, Krueger G, Xu W, Rahman M, Zribek J, Baratelle A, Beutler A. | J Rheumatol 2010;37:1326 | |||
| 2010 | Preliminary validation of the PsA MDA criteria according to the OMERACT filter. | Coates LC, Gladman DD, Cook R, Helliwell PS. | Ann Rheum Dis 2010;69(Suppl3):114. | |||
| 2010 | Peripheral blood gene expression profiling differentiates psoriatic arthritis from psoriasis without arthritis. | Gladman D, Pollock R, Virtanen C, Pellett F, Shanmugarajah S, Rosen C, Chandran V, | Ann Rheum Dis 2010;69(Suppl3):157. | |||
| 2010 | Association of ankylosing spondylitis susceptibility SNPS from recent GWAS in a Canadian psoriatic arthritis cohort. | Rahman P, Inman RD, Maksymowych WP, Udding M, Pope A, Gladman DD. | Ann Rheum Dis 2010;69(Suppl3):162. | |||
| 2010 | High level responses in psoriatic arthritis patients treated with golimumab: results from week 104 of the Go-REVEAL study. | Kavanaugh A, McInnes I, Krueger G, Gladman D, Zrubek J, Beutler A, Xu S, Mudivarthy S, Mack M, Mease P, Go-REVEAL investigators | Ann Rheum Dis 2010;69(Suppl3):585. | |||
| 2010 | Impact of adalimumab on work and activity impairment for patients with psoriatic arthritis | Mease P, Rao S, Cifaldi M, Chen N, Gladman D. | Ann Rheum Dis 2010;69(Suppl3):699. | |||
| 2010 | Impact of adalimumab treatment on physical function of patients with psoriatic arthritis with skin manifestations. | Mease PJ, Rao S, Cifaldi M, Chen N, Gladman D. | Ann Rheum Dis 2010;69(Suppl3):716. | |||
| 2010 | Soluble Biomarkers Predict Response to Anti-Tumour Necrosis Factor (TNF) Therapy in Psoriatic Arthritis (PsA) | Chandran V, Cook RJ, Pollock R, Pellett FJ, Shen H, Gladman DD. | J Rheumatol 2010;37:1282. | |||
| 2010 | Response to TNF -α Blockers in Psoriatic Arthritis – An Observational Cohort Study. | Eder L, Chandran V, Schentag C, Shen H, Cook RJ, Gladman DD. | J Rheumatol 2010;37:1285. | |||
| 2010 | Whole-genome transcriptional profiling for the evaluation of psoriasis-like mouse models | Swindell WR, Johnston A, Baerveldt E, Elder JT, Prens EP, Ward NL, Gudjonsson JE: | . J Invest Dermatol 130, suppl 1, A555, 2010. | |||
| 2010 | IL-1F5, F6, F8, and F9 represent an novel IL-1 signaling system which is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. | Johnston A, Xing X, Ward NL, Matheny CM, Riblett M, Guzman AM, Voorhees JJ, Elder JT, Gudjonsson JE: | J Invest Dermatol 130, suppl 1, A125, 2010. | |||
| 2010 | A role for the novel pro-inflammatory cytokine IL-17C in the pathogenesis of psoriasis. | Al-Attar PM, Gudjonsson JE, Ward NL, Riblett M, Xing X, Voorhees JJ, Elder JT, Johnston A: | J Invest Dermatol 130, suppl 1, A085, 2010. | |||
| 2010 | The psoriasis associated IL12B risk haplotype influences IL-12 and IL-23 expression and secretion. | Gudjonsson JE, Xing X, Nair RP, Voorhees JJ, Johnston A, JT Elder: | J Invest Dermatol 130, suppl 1, A119, 2010. | |||
| 2010 | : Psoriasis lesions are enriched in IL-22+ and IL-17+ T cells with an associated increase in the IL-17+/IL-13+ T cell ratio. | Rubin CJ, Riblett M, Lin A, Nair FJ, Elder JT, Bruce AT | J Invest Dermatol 130, suppl 1, A717, 2010. | |||
| 2010 | Amphiregulin carboxy-terminal domain regulates autocrine keratinocyte growth and differentiation. | Stoll SW, Rittie L, Elder JT: | J Invest Dermatol 130, suppl 1, A606, 2010. | |||
| 2010 | Polymorphisms in the obesity related FTO gene are associated with psoriasis. | Soltani-Arabshahi R, Feng B, Callis Duffin K, Goldgar DE, Hunt SC, Nair RP, Elder JT: | J Invest Dermatol 130, suppl 1, A538, 2010. | |||
| 2010 | IL-1F5, F6, F8, and F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. | Johnston A, Xing X, Guzman AM, Riblett M, Matheny CM, Ward NL, Voorhees JJ, Elder JT, Gudjonsson JE: | J Invest Dermatol 130, suppl 2, S43, 2010. | |||
| 2010 | Participation of IL-13 in the cytokine network of psoriasis. | Gudjonsson JE, Xing X, Riblett M, Kochkodan J, Guzman AM, Elder JT, Johnston A: | J Invest Dermatol 130, suppl 2, S15, 2010. | |||
| 2010 | IL-1F5, F6, F8, and F9: a novelIL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. | Johnston A, Xing X, Guzman AM, Riblett M, Matheny CM, Ward NL, Voorhees JJ, Elder JT, Gudjonsson JE: | Montagna Symposium on the Biology of Skin. Gleneden Beach, OR, October 2010. | |||
| 2010 | Environmental risk factors for psoriatic arthritis among patients with psoriasis – A case-control study | Eder L., Loo T, Kalman-Lamb G, Shen H, Cook R, Gladman DD | J Rheumatol 2010;37:1285. | |||
| 2010 | Environmental risk factors for psoriatic arthritis among patients with psoriasis – A case-control study. | Eder, L, Loo, T, Chandran V, Kalman-Lam G, Shanmugarajah S, Shen H, Cook R, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S809 | |||
| 2010 | Effectiveness and safety of Etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting | Gladman D, Bombarider C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M, Caveen M. | J Rheumatol 2010;37:1285. | |||
| 2010 | MICA Alleles Differentiate Skin and Joint Manifestations in Psoriatic Disease. | Pollock R, Yao C, Lino M, Shanmugarajah S, Pellett F, Chandran V, Gladman D. | J Rheumatol 2010;37:1305. | |||
| 2010 | Reliability of radiographic scoring methods in Axial Psoriatic Arthritis (AxPsA) | Biagioni BJ, Chandran V, Cook RJ, Eder L, Wakhlu A, Li M, Shen H, Gladman DD. | J Rheumatol 2010;37:1320. | |||
| 2010 | Macrophage Migration Inhibition Factor gene polymorphism is associated with relapse in joints that achieved remission after intra-articular steroid injection in psoriatic arthritis | Eder L, Chandran V, Ueng J, Bhella S, Lee K, Rahman P, Pope A, Cook RJ, Gladman DD. | . J Rheumatol 2010;37:1327. | |||
| 2010 | DC-STAMP (Dentritic Cell Specific Transmembrane Protein), a Potential biomarker to predict the risk of psoriasis patients in developing psoriatic arthritis. | Yahui GC, Shanmugarajah S, Oanpento B, Eder L, Chandran V, Gladman D, Moorehead S, Barrett R, Ritchlin CT. | Arthritis Rheum 2010;62(Suppl 10):S217. | |||
| 2010 | Differences in body mass index among individuals with psoriatic arthritis, psoriasis, rheumatoid arthritis and the general population. | Bhole VM, Choi HK, Burns LC, Keller CV, Lacaille DV, Gladman DD, Dutz JP. | Arhritis Rheum 2010;62(Suppl 10):S218. | |||
| 2010 | HLA-Cw*06 allele increases the duration of time between the onset of psoriasis and psoriatic arthritis. | Eder L, Pellett F, Chandran V, Shanmugarajah S, Gladman DD: | Arthritis Rheum 2010;62(Suppl 10):S220. | |||
| 2010 | Inflammation in an individual joint predicts damage to that join in psoriatic arthritis. | Chandran C, Cresswell C, Farewell V, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S223. | |||
| 2010 | Seasonal variation in Vitamin D levels in patients with psoriatic arthritis from northern and southern latitudes and its association with clinical outcomes. | Touma Z, Eder L, Chandran V, Rosen C, Schentag C, Cook R, Shen H, Gladman DD.: | Arthritis Rheum 2010;62(Suppl 10):S327. | |||
| 2010 | Abatacept (ABA) in the treatment of psoriatic arthritis (PsA): 12-month results of a phase 2 study. | Mease PJ, Genovese M, Gladstein GS, Kivitz AJ, Ritchling CT, Tak PP, wollenhaupt J, Becker JCP, Kelly SM, Peng Y, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S802. | |||
| 2010 | Comparison of Co-morbid disease burden in psoriasis and psoriatic arthritis (PsA). | Husted A, Thavaneswaran A, Chandran V, Eder L, Rosen, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S806. | |||
| 2010 | Dactylitis in psoriatic arthritis: Prevalence and response to therapy in the biologic era. | Ziouzina O, Thavaneswaran A, Chandran V, Gladman DD: | Arthritis Rheum 2010;62(Suppl 10):S808. | |||
| 2010 | Long-Term Radiographic Outcome in Psoriatic Arthritis Patients Treated with Golimumab: 104 Week Results from the GO-REVEAL Study. | Kavanaugh A, Van Der Heijde DM, Gladman DD, Mease PJ, McInnes IB, Krueger GG5, Xu W, Goldstein N, Beutler A. | Arthritis Rheum 2010;62(Suppl 10):S812. | |||
| 2010 | Reliability of radiographic scoring methods in axial psoriatic arthritis. | Chandran V, Biagioni B, Cook R, Lihi Eder, Wakhlu A, Li M, Shen H, Gladman DD: | Arthritis Rheum 2010;62(Suppl 10):S817. | |||
| 2010 | Smoking is negatively associated with development of psoriatic arthritis among psoriasis patient. | Eder L, Shanmugarajah S, Thavaneswaran A, Chandran V, Cook R, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S818. | |||
| 2010 | Association between Killer-cell immunoglobulin-like Receptor (KIR) gene polymorphisms and psoriatic arthritis. | Chandran V, Pellett V, Ayearst R, Pollock R, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S823. | |||
| 2010 | HLA-Bw4 alleles and HLA-C alleles that have high cell-surface expression are associated with susceptibility to psoriatic arthritis. | Chandran V, Pellett F, Ayearst R, Pollock R, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S826. | |||
| 2010 | HLA-B*27 and Cs*06 are risk alleles for psoriatic arthritis among psoriasis patients. | Eder L, Pellett F, Chandran V, Shanmugarajah S, Gladman DD.: | Arthritis Rheum 2010;62(Suppl 10):S826. | |||
| 2010 | MICA*016 differentiates skin and joint manifestations of psoriatic disease. | Chandran V, Pollock R, Barrett J, Eder L, Pellett F, Yao C, Lino M, Shanmugarajah S, Farewell V, Gladman DD. | Arthritis Rheum 2010;62(Suppl 10):S828. | |||
| 2010 | Differences in Body Mass Index among Individuals with Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and the General Population, | Vidula M Bhole , Hyon K Choi , Lindsay C Burns , Cristián Vera Kellet, Diane V Lacaille Arthritis , Dafna D Gladman and Jan P Dutz, | Poster, American College of Rheumatology Annual Meeting, November 2010. | |||
| 2010 | Use of Novel Hollow Microneedles for Transcutaneous Delivery ofMicroparticulate-encapsulated Antigen to the Skin as a Novel VaccinationStrategy, | Jacqueline Lai, Tullio Esposito, Urs Hafeli, Boris Stoeber, Jan Dutz, | Keystone Meeting Immunological Mechanisms of Vaccination, Oct 27, 2010, Seattle. | |||
| 2010 | Toll-Like Receptor 9 Expression on Hematopoietic-Derived Cells is Required for the Enhancement of Cytotoxic T Lymphocyte Priming by Topical CpG Adjuvant, | Wing Ki Cheng, Daniela Loeffler, Tobias R. Kollmann, Jan P. Dutz, | Poster, International Congress of Immunology, 2010. | |||
| 2010 | The Association of IL-13 polymorphism with Psoriatic Arthritis among Psoriasis Patients. | Eder L, Chandran V, Pellett F, Pollock R, Shanmagurajan S, Gladman DD. : | Arthritis Rheum 2010;62(Suppl 10):S830. | |||
| 2010 | : Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? | Gladman, DD, Thavaneswaran A, Chandran V | Arthritis Rheum 2010;62(Suppl 10):S956. | |||
| 2011 | EGFR and IL-1 synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. | Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT: | Journal of Investigative Dermatology, 131(2):329-37, 2011. PMCID: PMC3094455. | |||
| 2011 | Association between focal erosions and generalized bone loss in psoriatic arthritis. | Anandarajah AP, EL-Taha M, Peng C, Reed, G, Greenberg, JD, Ritchlin, CT. | Ann Rheum Dis. 2011:70(7):1345-7. PMID 21325427. | |||
| 2011 | Inflammation in an individual joint predicts damage to that joint in Psoriatic Arthritis. | Cresswell L, Chandran V, Farewell VT, Gladman DD. | Ann Rheum Dis 2011;70:305-308. | |||
| 2011 | The incidence of arthritis in a prospective cohort of psoriasis patients. | Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, Gladman DD. | Arthritis Care Res (Hoboken) 2011;63:619-622. | |||
| 2011 | Abatacept in the treatment of patients with psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled phase II trial. | Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D. | Arthritis Rheum 2011;63:939-948. | |||
| 2011 | Regulation of Human Osteoclast Development by Dendritic Cell Surface Transmembrane Protein (DC-STAMP) | Chu Y, Mensah K, Schwarz E, Ju Y, Feng C, McMahon L, Hicks D, Panepento B, Keng, P, Ritchlin CT. | . J Bone Min Res. 2011 Oct 10; DOI: 10.1002/jbmr.531 | |||
| 2011 | High resolution mapping in the MHC region identifies multiple independent novel loci for psoriatic arthritis. | Rahman P, Roslin NM, Pellett PJ, Lemire M, Greenwood CMT, Beyene J, Pope A, Peddle L, Paterson AD, Uddin M, Gladman DD. | Ann Rheum Dis 2011;70:690-694. | |||
| 2011 | Patient global assessment in psoriatic arthritis (PsA). A multicentre GRAPPA and OMERACT study. | Cauli C, Gladman D, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor W, Antonio Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden J, Lubrano E, Sueli C, Desiati F, Flynn JA, D’Angelo S, Vacca A, van Kuijk AWR, Catanoso MG, Gruenke M14, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell P, Mease P, for the GRAPPA 3PPsA study group. | J Rheumatol 2011;38:898-903. | |||
| 2011 | Repair of radiographic joint damage following treatment with a TNF inhibitor in psoriatic arthritis is demonstrable by three radiographic methods. | Eder L, Chandran V, Gladman DD. | J Rheumatol 2011;38:1066-1070. | |||
| 2011 | Differential MICA allele associations with skin and joint manifestations of psoriatic diseas. | Pollock R, Chandran V, Barrett J, Eder L, Pellett F, Yao C, Lino M, Shanmugarajah S, Vernon T. Farewell VT, Gladman DD. | Tissue Antigens 2011;77:554-561. | |||
| 2011 | Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE (Rating Evaluations in Psoriatic Arthritis with Enbrel) Trial. | Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poullin-Costello M. | J Rheumatol 2011;38:1355-1362. | |||
| 2011 | Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) -- Report of the OMERACT 10 PsA Special Interest Group. | Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG, McHugh NJ, Strand V, Gladman DD, Fitzgerald Ol. | J Rheumatol 2011;38:1496-1501 | |||
| 2011 | The association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. | Eder L, Law T, Chandran V, Kalman-Lamb G, Shanmugarajah S, Shen H, Cook RJ, Gladman DD. | Arthritis Care & Res 2011;63:1091-1097. | |||
| 2011 | IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. | Eder L, Chandran V, Pellett F, Pollock R, Shanmugarajah S, Rosen CF, Rahman P, Gladman DD. | Ann Rheum Dis 2011;70:1594-1598. | |||
| 2011 | Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. | Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, Wang X-J, Sano S, Prens EP, DiGiovanni J, Pittelkow MR, Ward NL, Gudjonsson JE: | PLoS One 6(4):e18266, 2011. PMCID: PMC3071727. | |||
| 2011 | Pervasive sharing of genetic effects in autoimmune disease. | Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, Abecasis G, Barrett JC, Behrens T, Cho JH, de Jager PL, Elder JT, Graham RR, Gregersen P, Klareskog L, Siminovich K, van Heel DA, Wijmenga C, Worthington J, Todd JA, Hafler DA, Rich SS, Daly MJ: | PLoS Genetics Aug;7(8):e1002254, 2011. PMCID: PMC3154137. | |||
| 2011 | Seasonal Variation in Vitamin D Levels in Psoriatic Arthritis Patients from Different Latitudes and its Association with Clinical Outcomes. | Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen Cheryl, Shen H, Cook RJ, Gladman D. | Arthritis Care Res Online 2011/07/11. | |||
| 2011 | Expression Patterns of Natural Killer Receptor Genes in Inflamed Joints and Peripheral Blood of Patients with Psoriatic Arthritis. | Pollock RA, Pellett PJ, Chandran C, Gladman DD. | Tissue Antigens Online 2011/08/24. | |||
| 2011 | Human Leukocyte Antigen risk alleles for Psoriatic Arthritis among psoriasis patients. | Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, Gladman DD. | Ann Rheum Dis Online 2011/09/06. | |||
| 2011 | Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. | Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD. | Arthritis Care & Res Online 2011/09/08. | |||
| 2011 | Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? | Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. | Ann Rheum Dis online 2011/09/12. | |||
| 2011 | The association between smoking and the development of psoriatic arthritis among psoriasis patients. | Eder L, Shanmugarajah S, Thavaneswaran A, ChandranV, Rosen CF, Cook RJ, Gladman DD. | Ann Rheum Dis Online 2011/09/29. | |||
| 2011 | Patient reported outcome in psoriatic arthritis: a Comparison of web based versus paper completed questionnaires. | McKenzie H, Thavaneswaran A, Chandran V, Gladman DD. | J Rheumatol (In Press). | |||
| 2011 | A comparison of the quality of life of people with psoriatic arthritis (PsA) and those with psoriasis only (PsC). | Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. | Rheumatology (In press). | |||
| 2011 | Differences in Body Mass Index among Individuals with Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and the General Population. | Bhole VM, Choi HK, Burns LC, Kellet CV, Lacaille DV, Gladman DD, Dutz JP. | J Rheum (in Press). | |||
| 2011 | The prevalence of monoclonal gammopathy among patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Pereira D, Sussman G, Gladman DD. | J Rheumatol (In Press) | |||
| 2011 | Utility of interferon gamma release assays in the diagnosis of erythema induratum – Clinical Observation. | Vera-Kellet, C, Peters, L, Elwood, K, Dutz, JP. | Arch Dermatol. 2011 Aug;147(8):949-52. | |||
| 2011 | Reversible retiform purpura: a sign of cocaine use. | Han, C, Sreenivasan, G, Dutz, JP. | CMAJ. 2011 Jun 14;183(9):E597-600. Epub 2011 Mar 14. | |||
| 2011 | Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. | Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, Wang X, Sano S, Prens EP, Digiovanni J, Pittelkow MR, Ward NL, Gudjonsson JE | J Invest Dermatol 131, suppl 1, A013, 2011. | |||
| 2011 | Heterogeneity in the inflammatory network in chronic plaque psoriasis. | Swindell WR, Xing X, Chen C, Nair RP, Voorhees JJ, Elder JT, Johnston A, Gudjonsson JE | J Invest Dermatol 131, suppl 1, A019, 2011. | |||
| 2011 | Erlotinib-stimulated epidermal hyperplasia is mediated by IL-1. | Ward NL, Bhagavathula N, Loyd CM, Dawes S, Johnston A, Varani J, Elder JT | J Invest Dermatol 131, suppl 1, A025, 2011. | |||
| 2011 | IL-17C is overexpressed in psoriasis skin and contributes to cytokine-driven inflammation. | Chen CS, Al-Attar PM, Fu W, Loyd CM, Riblett MB, Xing X, Voorhees JJ, Elder JT, Ward NL, Gudjonsson JE, Johnston A | J Invest Dermatol 131, suppl 1, A027, 2011. | |||
| 2011 | TRAF3IP2 couples IL-17 to the epidermal defense response. | Lambert S, Stoll SW, Elder JT | J Invest Dermatol 131, suppl 1, A034, 2011. | |||
| 2011 | Amphiregulin precursor controls cell-cycle regulatory gene expression in human keratinocytes. | Stoll SW, Ritté L, Lambert S, Prasad M, Gudjonsson JE, Li B, Wei Y, Abecasis G, Stuart PE, Nair RP, Elder JT | J Invest Dermatol 131, suppl 1, A157, 2011. | |||
| 2011 | Genetic associations of psoriasis in a Pakistani population. | Shaiq PA, Stuart PE, Raja GK, Voorhees JJ, Elder JT, Qamar R, Nair RP | J Invest Dermatol 131, suppl 1, A376, 2011. | |||
| 2011 | Interaction between psoriasis susceptibility loci ERAP1 and HLA-Cw6. | Tejasvi T, Stuart PE, Nair RP, Voorhees JJ, Elder JT | J Invest Dermatol 131, suppl 1, A390, 2011. | |||
| 2011 | Heterogeneity of inflammatory and cytokine Networks in chronic plaque psoriasis. | Aphale A, Swindell W, Stuart P, Chen C, Xing X, Nair R, Voorhees J, Elder J, Johnston, A, Gudjonsson, J | J Invest Dermatol 131, suppl 2, A114, 2011. | |||
| 2011 | TRAF3IP2 Couples IL-17 to the Epidermal Defense Response. | Lambert S, Stoll SW, Johnston A, Elder JT | J Invest Dermatol 131, suppl 2, 2011. | |||
| 2011 | Seasonal Variation in Vitamin D Levels in Patients with Psoriatic Arthritis from Northern and Southern Latitudes and its Association with Clinical Outcomes. | Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen C, Shen H, Cook RJ, Gladman DD | J. Rheumatol. In Press. | |||
| 2011 | The Functional MICA-129 Polymorphism is Associated with Psoriatic Diseease Independently of HLA-B and C. | Pollock R, Chandran V, Barrett J, Eder L, Pellett F, Yao C, LIno M, Shanmugarajah S, Farewell V, Gladman DD | J. Rheumatol. In Press. | |||
| 2011 | Prevalence of Metabolic Syndrome in Psoriasis and Psoriatic Arthritis. | Jayakar JP, Eder L, Pereira D, Thavaneswaran A, Shanmugarajah S, and Gladman DD: | J. Rheumatol. In Press. | |||
| 2011 | Psoriatic arthritis (PsA) in Canadian Clinical Practice: the PsA Assessment in Rheumatology (PAIR) | Gladman DD, Chandran V, Thavaneswaran A, Zummer M | J. Rheumatol. In Press. | |||
| 2011 | Early and sustained remission associated with normalized physical function, health-related quality of life & significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: 2-year data from phase iii GO-REVEAL trial. | Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mudivarthy S, Mack M, Tandon N, Han C, Mease P, GO-REVEAL Clinical Investigators. | Ann Rheum Dis 2011;70(Suppl3):238. | |||
| 2011 | Sensitivity to change of radiographic scoring instruments in axial psoriatic arthritis. | Chandran V, Ibrahim A, Thavaneswaran A, Eder L, Helliwell P, Cook J, Gladman DD. | Ann Rheum Dis 2011;70(Suppl3):239. | |||
| 2011 | Prevalence of known obesity related genes differs between psoriatic arthritis and psoriasis. | Uddin M, Hamilton S, Eder L, Pellett F, Pope A, Peddle L, Gladman D, Rahman P. | Ann Rheum Dis 2011;70(Suppl3):239. | |||
| 2011 | Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study. | Kavanaugh A, van der Heijde D, Gladman D, Mease P, McInnes I, Krueger GG, Xu G, Goldstein N, Beutler A, GO-REVEAL Clinical Investigators. | Ann Rheum Dis 2011;70(Suppl3):240. | |||
| 2011 | The Interaction between Killer-cell Immunoglobulin-like Receptor Genes and HLA Alleles in Susceptibility to Psoriatic Arthritis. | Chandran V, Pellett FJ, Ayearst R, Pollock RA, Gladman DD. | ASHG/ICHG 2011 Montreal, Canada, October 11-15. (Accepted). | |||
| 2011 | The association between Human Leukocyte Antigen and Killer-cell Immunoglobulin-like receptor gene variants and the development of Axial Arthritis among Patients with Psoriatic Arthritis. | Chandran V, Thavaneswaran A, Pellett FJ, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Investigating the association between endoplasmic reticulum aminopeptidase 1 gene variants and psoriatic arthritis. | Chandran V, Pellett FJ, Pollock RA, Ayearst R, Rahman P, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | The association between Human Leukocyte Antigen and Killer-cell Immunoglobulin-like receptor gene variants and progression of peripheral joint damage in psoriatic arthritis. | Chandran V, Thavaneswaran A, Pellett FJ, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Serum Kallikreins as Biomarkers in Psoriatic Disease. | Eissa A, Gladman DD, Thavaneswaran A, Pellett FJ, Diamandis E, Chandran V. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Extended Haplotypes Between Human Leukocyte Antigen - C and Tumour Necrosis Factor A gene loci Reveal Psoriatic Arthritis Susceptibility Hotspots. | Pollock RA, Pellett FJ, Ayearst R, Rahman P, Gladman DD, Chandran V. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | The association between Human Leukocyte Antigen and Killer-cell Immunoglobulin-like receptor gene variants and the development of arthritis mutilans in patients with psoriatic arthritis. | Chandran V, Thavaneswaran A, Pellett FJ, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Association between Human Leukocyte Antigen and Killer-cell Immunoglobulin-like receptor gene variants and type II psoriasis and dactylitis in Psoriatic Arthritis. (Accepted). | Chandran V, Pellett FJ, Thavaneswaran A, Pollock RA, Ayearst R, Gladman DD. | Arthritis Rheum 2011;63(supplement) | |||
| 2011 | Family based association study confirms human leukocyte antigen allele associations with psoriatic arthritis. | Chandran V, Pellett FJ, Rahman P, Gladman DD. | Arthritis Rheum 2011;63(supplement) | |||
| 2011 | Radiographic scoring instruments have high specificity for detecting change in axial psoriatic arthritis. | Chandran V, Ibrahim A, Thavaneswaran A, Eder L, Helliwell P, Cook RJ, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Proteomic Profiling of Synovial Fluid for the Identification of Psoriatic Arthritis Soluble Biomarkers. | Cretu D, Gladman DD, Pellett FJ, Diamandis E, Chandran V. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Does clinical examination underestimate joint inflammation in patients with psoriatic arthritis? | Gladman DD, Cook RJ, Eder L, Wakhlu A, Riddell C, Ostergaard M, Thavaneswaran A, Chandran V. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Comparison Between Psoriasis and Psoriatic Arthritis in an International Cohort. | Gladman DD, Ayearst A, Chandran V, Dutz JP, Elder JT, Ritchlin C, Rosen CF, Rahman P. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Differential Human Leukocyte Allele Association between Psoriasis and Psoriatic Arthritis – A Family-Based Association study. | Eder L, Pellett FJ, Chandran V, Shanmugarajah S, Bull SB, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Anti TNFα agents are more effective than methotrexate in preventing radiographic joint damage among patients with Psoriatic Arthritis in a clinic setting. | Eder L, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Gender related differences in severity of Psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(Supplement) Accepted | |||
| 2011 | The Prevalence of Carotid Artery Plaques Is Higher in Patients with Psoriatic Arthritis Compared to Those with Psoriasis Alone. | Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, Rosen CF, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Serum levels of Adiponectin and Insulin Resistance are increased in patients with Psoriatic Arthritis compared to those with Psoriasis alone. | Eder L, Pollock RA, Pellett FJ, Jayakar J, Thavaneswaran A, Pereira D, Rosen CF, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Radiological Characteristics of the Calcaneal Spurs in Psoriatic Arthritis. | Abufayyah M, Salonen D, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | The incidence of infection in psoriatic arthritis - results from longitudinal observational cohort. | Haddad A, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | The predictors of infection in psoriatic arthritis - results from longitudinal observational cohort. | Haddad A, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | The effectiveness of Leflunomide in Psoriatic Arthritis. | Asiri A, Thavaneswaran A, Chandran V, Kalman-Lamb G, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Does the change in season affect disease outcomes in patients with psoriatic arthritis? | Touma Z, Thavaneswaran A, Chandran V, Gladman DD. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | Expression of DC-STAMP (Dendritic Cell-Specific Transmembrane Protein) and Osteoclast Precursor (OCP) Frequency in Psoriasis (PsC) patients who develop Psoriatic Arthritis (PsA). | Chiu YG, Shanmugarajah S, Panepento B, Moorehead S, Eder L, Chandran V, Gladman DD, Ritchlin CT. | Arthritis Rheum 2011;63(supplement) (Accepted). | |||
| 2011 | HLA- B*27 and HLA-C*0602 are risk alleles for psoriatic arthritis among psoriasis patients. | Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, Gladman DD. | British Journal of Dermatology (Accepted). | |||
| 2011 | Gene environment interaction in psoriasis and psoriatic arthritis: smoking and HLA-C*0602. | Eder L, Shanmugarajah S, Thavaneswaran A, Chandran V, Rosen CF, Cook RJ, Gladman DD. | British Journal of Dermatology (Accepted). | |||
| 2011 | Prevalences of physician-diagnosed depression and related mood disorders among patients with psoriatic arthritis: A population-based study. | Wall-Burns L, Choi H, De Vera M, Rahman M, Dutz JP. | GRAPPA Annual Meeting, Naples 2011 [Best Oral Presentation Award] | |||
| 2011 | A comparison of methotrexate use amongst dermatologists and rheumatologists in Canada. | Dupuis E, Dutz JP. | GRAPPA Annual Meeting, Naples 2011 [Meritorious Poster Award | |||
| 2011 | A novel defect in Fibrillin-1 deposition by dermal fibroblasts clinically presenting as localized elastolysis is reversible with dexamethasone and losartan treatment, Poster | Anna Hinek, Aleksander Hinek, Jan Dutz | American Academy of Dermatology, February 2011. | |||
| 2011 | Antiphospholipid antibody syndrome triggered by levamisole-tainted cocaine: Case report and review of the literature, Poster | Christina Han and Jan Dutz | American Academy of Dermatology, February 2011 | |||
| 2012 | Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). | Chiu YH, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, McMahon LA, Hicks DG, Panepento B, Keng PC, Ritchlin CT. | J Bone Miner Res. 2012 Jan;27(1):79-92. PMCID: PMC3304467 | |||
| 2013 | Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. | Eissa A, Cretu D, Soosaipillai A, Thavaneswaran A, Pellett F, Diamandis A, Cevikbas F, Steinhoff M, Diamandis EP, Gladman D, Chandran V. | Clin Chem Lab Med. 2013 Feb;51(2):317-25. | |||
| 2013 | Delineating the synovial fluid proteome: recent advancements and ongoing challenges in biomarker research. | Cretu D, Diamandis EP, Chandran V. | Crit Rev Clin Lab Sci. 2013 Feb-Apr;50(2):51-63. | |||
| 2013 | Genetic associations of psoriasis in a Pakistani population. | Shaiq PA, Stuart PE, Latif A, Schmotzer C, Kazmi AH, Khan MS, Azam M, Tejasvi T, Voorhees JJ, Raja GK, Elder JT, Qamar R, Nair RP | British Journal of Dermatology 169(2):406-11, 2013. | |||
| 2014 | Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. | Mease PJ, Garg A, Helliwell PS, Park JJ, Gladman DD. | J Rheumatol 2014;41:1249-1251. | |||
| 2013 | Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. | Eissa A, Cretu D, Soosaipillai A, Thavaneswaran A, Pellett F, Diamandis A, Cevikbas F, Steinhoff M, Diamandis EP, Gladman D, Chandran V. | Clin Chem Lab Med. 2013;51(2):317-25. | |||
| 2013 | Delineating the synovial fluid proteome: recent advancements and ongoing challenges in biomarker research. | Cretu D, Diamandis EP, Chandran V. | Crit Rev Clin Lab Sci. 2013;50(2):51-63. | |||
| 2013 | Characterization of DC-STAMP+ Cells in Human Bone Marrow. | Chiu YG, Ritchlin CT. | J Bone Marrow Res. 2013 Jul 19;1. pii: 1000127. PMCID: PMC4238037 | |||
| 2014 | Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. | Cretu D, Prassas I, Saraon P, Batruch I, Gandhi R, Diamandis EP, Chandran V. | Clin Proteomics. 2014 Jul 1;11(1):27. | |||
| 2014 | Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides new insights into disease mechanisms. | Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A, Ding J, Stuart PE, Xing X, Voorhees JJ, Kang HM, Nair RP, Abecasis GR, Elder JT | Journal of Investigative Dermatology 134(7):1828-38, 2014. | |||
| 2014 | Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Gladman DD. | Ann Rheum Dis 2014;73:1007-1011. | |||
| 2014 | The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. | Eder L, Chandran V, Gladman DD. | Ann Rheum Dis 2014; 73:1990-1996. | |||
| 2014 | Killer immunoglobulin-like receptor gene polymorphism and susceptibility to psoriatic arthritis. | Chandran V, Bull SB, Pellett FJ, Ayearst R, Pollock RA, Gladman DD. | Rheumatology 2014;53:233-239. | |||
| 2014 | Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis. | Kennedy M, Papneja A, Thavaneswaran A, Chandran V, Gladman DD. | Clin Exp Rheumatol 2014;32: 342-348. | |||
| 2014 | Radiological characteristics of the calcaneal spurs in psoriatic arthritis. | Gladman DD, Abuffayah M, Salonen D, Thavaneswaran A, Chandran V. | Clin Exp Rheumatol 2014;32:401-403. | |||
| 2014 | Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls? | Eder L, Jayakar J, Thavaneswaran A, Haddad A, Chandran V, Salonen D, Rosen C, Gladman DD. | J Rheumatol 2014;41:466-472. | |||
| 2014 | Development of a Disease Activity and Responder Index for Psoriatic Arthritis. -- Report of the Psoriatic Arthritis Module at OMERACT 11. | Coates LC, Fitzgerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS. | J. Rheumatol 2014;41:782-791. | |||
| 2014 | Depression and anxiety in psoriatic disease: prevalence and associated factors. | McDonough E, Thavaneswaran A, Ayearst R, Eder L, Chandran V, Rosen CF, Gladman DD. | J Rheumatol 2014;41:887-896. | |||
| 2014 | Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of the RAPID-PsA Study. | Gladman DD, Fleischmann MD, Cotuer G, Woltering F, Mease M. | Arthritis Care Res (Hoboken) 2014;66:1085-1098. | |||
| 2014 | Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. | Okada Y, Han B, Tsoi L, Stuart PE, Ellinghaus E, Tejasvi T, Chadnran V, Pellette F, Pollock R, Bowcock AM, Krueger GG, Weichenthal, M, Voorhess JJ, Rahman P, Gregersen PK, Franke A, Nair RP, Abecasis GR, Gladman DD, Elder JT, de Bakker PIW, Raychaudhuri S. | J Hum Gen 2014;95:162-172. | |||
| 2014 | Reliability of radiographic scoring methods in axial psoriatic arthritis. | Biagioni B, Gladman DD, Cook RJ, Eder L, Wakhlu A, Hua S, Chandran V. | Arthritis Care Research (Hoboken). 2014;66:1417-1422. | |||
| 2014 | The Effectiveness of Leflunomide in psoriatic arthritis. | Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. | Clin Exp Rheumatol 2014;32:728-731. | |||
| 2014 | Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. | Mease PJ, Gladman DD, Helliwell PS, Khraishi MM, Fuiman J, Bananis E, Alvarez Dl. | J Am Acad Dermatol online 2014;71:649-655. | |||
| 2014 | Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. | Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke WH, Langley RG, Lubrano E, Maccarone M, Schulze-Koops H, Miceli-Richard C, Queiro R. | Arthritis Care Res (Hoboken ) 2014;12: 1759-66. | |||
| 2014 | Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. | Ann Rheum Dis Online 2014/01/15. | |||
| 2014 | Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. | Ann Rheum Dis. Online 2014/05/14. | |||
| 2014 | Improvements in productivity at paid work and within the household and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. | Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. | Ann Rheum Dis Online 2014/06/18. | |||
| 2014 | Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. | Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. | Arthritis Care Res (Hoboken) Online 2014/07/21. | |||
| 2014 | Fine mapping of eight psoriasis susceptibility loci. | Das S, Stuart PE, Ding J, Tejasvi T, Li Y, Tsoi LC, Chandran V, Fischer J, Helms C, Duffin KC, Voorhees JJ, Bowcock AM, Krueger GG, Lathrop GM, Nair RP, Rahman P, Abecasis GR, Gladman D, Elder JT. | Eur J Hum Genet Online 2014/09/03. | |||
| 2014 | Gene expression differences between psoriasis patients with and without inflammatory arthritis. | Pollock RA, Fatima Abji F, Liang K, Chandran V, Pellett F, Virtanen C, Gladman DD. | J Invest Dermatol 2014/09/22. | |||
| 2014 | Immunoglobulin G Subclass Analysis in Psoriatic Arthritis. | Haddad A, Thavaneswaran A, Abji F, Pellett F, Chandran V, Wither J, Gladman DD. | J Rheumatol Online 2014/1015. | |||
| 2014 | Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. | Cretu D, Prassas I, Saraon P, Batruch I, Gandhi R, Diamandis EP, Chandran V. | Clin Proteomics. 2014;11(1):27. | |||
| 2014 | Fine-mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. | Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, Chandran V, Pellett F, Pollock R, Bowcock AM, Krueger GG, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke F, Nair R, Abecasis GR, Gladman DD, Elder JT, de Bakker PIW, Raychaudhuri S | American Journal of Human Genetics 95(2):162-72, 2014. PubMed PMID: 25087609; PubMed Central PMCID: PMC4129407. | |||
| 2014 | Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy. | Rosenberg A, Fan H, Chiu YG, Bolce R, Tabechian D, Barrett R, Moorehead S, Baribaud F, Liu H, Peffer N, Shealy D, Schwarz EM, Ritchlin CT. | PLoS One. 2014 Oct 21;9(10):e110657. doi: 10.1371/journal.pone.0110657. PMCID: PMC4204991 | |||
| 2014 | Minimal disease activity and anti-TNF Therapy in psoriatic arthritis. | Haddad A, Thavaneswaran A, Arruza IR, Pellett F, Chandran V, Cook RJ, Gladman DD. | Arthritis Care Res.(Hoboken.) 2015;67:842-847. | |||
| 2015 | Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study. | Eder l, Chandran V, Rosen C, Dutz J, Elder JT, Rahman P, Ritchlin CT, Tausk FA, Rohekar S, Haday R, Barac S, Zisman D, Feld J, Gladman DD. | Arthritis Rheumatol 2015;67(Suppl 10):Abstract 3117. | |||
| 2015 | Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. | Ann Rheum Dis 2015;74:813-817. | |||
| 2015 | Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. | Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. | Ann Rheum Dis 2015;74:1830-1835. | |||
| 2015 | Gene expression differences between psoriasis patients with and without inflammatory arthritis. | Pollock RA, Abji F, Liang K, et al. | J Invest Dermatol 2015;135:620-3. | |||
| 2015 | CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients. | Muntyanu A, Abji F, Liang K. Chandran V, Gladman DD. | Arthritis Rheumatol 2015;67(Suppl 10):Abstract 2834. | |||
| 2015 | Fine mapping of eight psoriasis susceptibility loci. | Das S, Stuart PE, Ding J, Tejasvi T, Li Y, Tsoi LC, Chandran V, Fischer J, Helms C, Callis Duffin K, Voorhees JJ, Bowcock, AM, Krueger GG, Lathrop GM, Nair RP, Rahman P, Abecasis GR, Gladman DD, Elder JT: | European Journal of Human Genetics 23(6):844-53, 2015. | |||
| 2015 | Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. | Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, Tejasvi T, Kang HM, Allen MH, Lambert S, Stoll S, Weidinger S, Gudjonsson JE, Koks S, Kingo K, Esko T, Weichenthal M, Voorhees JJ, Chandran V, Rosen CF, Rahman P, Gladman DD, Reis A, Collaborative Association Study of Psoriasis, Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Nair RP, Franke A, Barker JNWN, Abecasis GR, Trembath RC, Elder JT: | Nature Communications 6:7001, 2015. | |||
| 2015 | Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. | Lenz TL, Deutsch AJ, Han B, Hu XY, Okada Y, Eyre S, Knapp M, Zhernakova A, Huizinga TWJ, Abecasis A, Becker Boeckxstaens GE Chen W-M, Franke A, Gladman DD, Gockel I, Gutierrez-Achury J, Martin J, Nair RP, Nöthen MM, Onengut-Gumuscu S, Rahman P, Rantapää-Dahlqvist S, Stuart PE, Tsoi LC, van Heel DA, Worthington J, Wouters MM, Klareskog L, Elder J, Gregersen PK, Schumacher J, Rich SS, Wijmenga S, Sunyaev SR, de Bakker PIW, Raychaudhuri S: | Nature Genetics 47(9):1085-90, 2015. | |||
| 2015 | Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. | Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ,2 Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke F, Gladman DD, Abecasis GR, Elder JT | American Journal of Human Genetics 97(6):816-36, 2015. | |||
| 2016 | Group for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015. | Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta Felquer M, Armstrong AW, Bautista Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni EM, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT. | Arthritis Rheumatol 2016;68:1060-1071. | |||
| 2015 | Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. | Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, Tejasvi T, Kang HM, Allen MH, Lambert S, Stoll S, Weidinger S, Gudjonsson JE, Koks S, Kingo K, Esko T, Weichenthal M, Voorhees JJ, Chandran V, Rosen CF, Rahman P, Gladman DD, Reis A, Collaborative Association Study of Psoriasis, Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Nair RP, Franke A, Barker JNWN, Abecasis GR, Trembath RC, Elder JT. | Nature Communications 6:7001, 2015 | |||
| 2015 | Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. | Lenz TL, Deutsch AJ, Han B, Hu XY, Okada Y, Eyre S, Knapp M, Zhernakova A, Huizinga TWJ, Abecasis A, Becker Boeckxstaens GE Chen W-M, Franke A, Gladman DD, Gockel I, Gutierrez-Achury J, Martin J, Nair RP, Nöthen MM, Onengut-Gumuscu S, Rahman P, Rantapää-Dahlqvist S, Stuart PE, Tsoi LC, van Heel DA, Worthington J, Wouters MM, Klareskog L, Elder J, Gregersen PK, Schumacher J, Rich SS, Wijmenga S, Sunyaev SR, de Bakker PIW, Raychaudhuri S: | Nature Genetics 47(9):1085-90, 2015. PMCID:PMC4552599. | |||
| 2015 | Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. | Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ,2 Ritchlin CT, Bowcock AM Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke F, Gladman DD, Abecasis GR, Elder JT: | American Journal of Human Genetics 97(6):816-36, 2015. PMCID:PMC4678416. | |||
| 2015 | Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. | Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT. | Am J Hum Genet 2015 Dec 3;97(6):816-36. | |||
| 2016 | The incidence and risk factors for psoriatic arthritis in patients with psoriasis - a prospective cohort study. | Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, Gladman DD. | Arthritis Rheumatol 2016;68:915-923. | |||
| 2016 | Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. | Eder L, Wu Y, Chandran V, Cook R, Gladman DD. | Ann Rheum Dis 2016;75:1680-1686. | |||
| 2016 | The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. | Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD. | J Rheumatol 2016; 43:362-6. | |||
| 2016 | Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. | Sheane BJ, Thavaneswaran A, Gladman DD, Chandran V. | J Rheumatol online 2016;43:1718-1723. | |||
| 2016 | Clinical and demographic characteristics of erosion-free and erosion-present status in psoriatic arthritis in a Prospective cohort study. | Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook R, Gladman D. | J Rheumatol 2016;43:1057-1062. | |||
| 2016 | C-X-C Motif Chemokine 10 is a Possible Biomarker for the Development of Psoriatic Arthritis among Patients with Psoriasis. | Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. | Arthritis Rheumatol online 2016/07/07. | |||
| 2016 | Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. | Ellinghaus D, Jostens L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hubenthal M, Folseraas T, Wang Y, Esko T, Metspalu A, Westra HJ, Franke, L, Pers T, Degenhardt F, Forstner A, Hofmann A; International IBD Genetics Consortium (IIBDGC); International Genetics of Ankylosing Spondylitis Consortium (IGAS); International PSC Study Group (IPSCSG); Genetic Analysis of Psoriasis Consortium (GAPC); Psoriasis Association Genetics Extension (PAGE), Schreiber S, Mroweitz U, Juran BD, Lazaridis KN, Brunak S, Dale AM, Trembath RC, Weidinger S, Weichenthal M, Ellinghaus E, Elder JT, Barker JN, Andreassen OA, McGovern DP, Karlsen TH, Barrett JC, Brown MA, Franke A: | Nature Genetics, 2016 May;48(5):510-8. PMID:26974007 PMCID: PMC4848113 | |||
| 2016 | The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. | Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD. | J Rheumatol 2016; 43:362-366. | |||
| 2016 | Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. | Sheane BJ, Thavaneswaran A, Gladman DD, Chandran V. | J Rheumatol 2016;43:1718-1723. | |||
| 2016 | Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. | Chandran S, Aldei A, Johnson SR, Cheung AM, Salonen D, Gladman DD. | Semin Arthritis Rheum 2016;46:174-182. | |||
| 2016 | The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. | Eder L, Abji F, Rosen CF, Chandran V, Cook RJ, Gladman DD. | J Rheumatol 2016;43:1844-1851. | |||
| 2016 | C-X-C Motif Chemokine 10 is a Possible Biomarker for the Development of Psoriatic Arthritis among Patients with Psoriasis. | Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. | Arthritis Rheumatol 2016;68:2911-2916. | |||
| 2016 | Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. | Muntyanu A, Abji F, Liang K, Pollock RA, Chandran V, Gladman DD. | Arthritis Res Ther 2016;18:296. | |||
| 2017 | Should methotrexate remain the first-line drug for psoriasis? (Comment). | Gladman DD. | Lancet 2017;389:482-483. | |||
| 2017 | Epigenetics of Psoriatic Disease: A Systematic Review and Critical Appraisal. | Pollock RA, Abji F, Gladman DD. | J Autoimmun 2017;78:29-38. | |||
| 2017 | Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change. | Maldonado-Ficco H, Sheane BJ, Thavaneswaran A, Chandran V, Gladman DD. | J Clin Rheumatol 2017;23:243-245.. | |||
| 2017 | Treating psoriasis and psoriatic arthritis: Position paper on applying treat-to-target concept to Canadian daily practice. | Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanaan C, Gooderham MJ, Gulliver WP, Ho VC, Hong CH, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, rohekar S, Rsoen CF, Russell AS, Vender RB, Yeung J, Ziouzina O, Zummer M. | J Rheumatol 2017; 44: 519-534. | |||
| 2017 | The development of PsA in patients with psoriasis is preceded by a period of non-specific musculoskeletal symptoms: A prospective cohort study. | Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD. | Arthritis Rheumatol 2017;69:622-629. | |||
| 2017 | Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. | Polachek A, Li S, Polachek IS, Chandran V, Gladman D. | Semin Arthritis Rheum 2017;46:740-745 | |||
| 2017 | The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis – A Cohort Study. | Eder L, Chandran V, Cook R, Gladman DD. | J Rheumatol 2017;44:286-291. | |||
| 2017 | The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes. | Zisman D, Gladman DD, Stoll ML, Strand V, Lavi I, Hsu JJ, Mellins ED, and the CARRA Legacy Registry Investigators. | J Rheumatol 2017;44:342-351. | |||
| 2017 | Psoriatic Arthritis. | Ritchlin CT, Colbert RA, Gladman DD. | New Engl J Med 2017:376:957-970. | |||
| 2017 | Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. | Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran V, Dand N, Duffin KC, Enerbäck C0, Esko T, Franke A, Gladman DD, Hoffmann P, Kingo K, Kõks S, Krueger GG, Lim HW, Metspalu A, Mrowietz U, Mucha S, Rahman P, Reis A, Tejasvi T, Trembath R, Voorhees JJ, Weidinger S, Weichenthal M, Wen X, Eriksson N, Kang HM, Hinds DA, Nair RP, Abecasis GR, Elder JT. | Nat Commun 2017;8:15382. | |||
| 2017 | Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics and outcome. | Polachek A, Li S, Chandran V, Gladman D. | Arthritis Care & Res 2017;69:1685-1691. | |||
| 2017 | Radiographic scoring instruments have moderate sensitivity but high specificity for detecting change in axial psoriatic arthritis. | Ibrahim A, Gladman DD, Thavaneswaran A, Eder L, Helliwell P, Cook RJ, Chandran V. | Arthritis Care Res 2017;69:1700-1705. | |||
| 2017 | Sleep disturbance in psoriatic disease: Prevalence and associated factors. | Wong ITY, Chandran V, Li S, Gladman DD. | J Rheumatol 2017 44:1369-1374. | |||
| 2017 | The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. | Polachek A, Cook R, Chandran V, Gladman DD, Eder L. | Arthritis Res Ther Online 2017; 19(1):180. | |||
| 2017 | Association of variably expressed KIR3DL1 alleles with psoriatic disease. | Beirnstein J, Pollock R Pellett F, Thavaneswaran A , Chandran C, Gladman DD. | Clin Rheumatol 2017;36:2262-2266. | |||
| 2017 | Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. | Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. | New Engl J Med 2017;377:1525-1536. | |||
| 2017 | TNF-alpha inhibitors are associated with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. | Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, Mehta NN. | J Rheumatol online 2017/10/31. | |||
| 2017 | Th17 Gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneious psoriasis. | Abji F, Pollock R, Liang K, Chandran V, Gladman DD. | Clin Exp Rheumatol online 2017/11/09 (in press). | |||
| 2017 | Novel serum biomarkers differentiate psoriatic arthritis from psoriasis without psoriatic arthritis. | Cretu D, Gao L, Liang K, Soosaipillai A, Diamandis EP, Chandran V. | Arthritis Care Res (Hoboken) 2017/06/06. | |||
| 2017 | GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. | Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS. | Arthritis Rheumatol online 2017/11/28. | |||
| 2017 | Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. | Aljohani R, Polachek A, Ye J, Chandran V, Gladman DD. | J Rheumatol Online. 2017/12/01 | |||
| 2017 | Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signaling. | Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Duffin KC, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN. | Human Molecular Genetics 2017;26:4301-4313. | |||
| 2017 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. | Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, de Wit M, Aletaha D, Baraliakos X, Betteridge N, vad der Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, de Vlam K, vad der Heijde D. | Ann Rheum Dis 2018;77:3-17. | |||
| 2017 | : A rare coding allele in IFIH1 is protective for psoriatic arthritis. | Budu-Aggrey A, Bowes J, Stuart PE, Zawistowski M, Tsoi LC, Nair RP, Korendowych E, McHugh NJ, Elder JT, Barton A, Raychaudhuri S | Annals of the Rheumatic Diseases, 76(7)1321-1324, 2017. PMCID:PMC5530346 | |||
| 2017 | Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. | Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran V, Dand N, Callis Duffin K, Enerbäck C, Esko T, Franke A, Gladman DD, Hoffmann P, Kingo K, Kõks S, Krueger GG, Lim HW, Metspalu A, Mrowietz U, Mucha S, Rahman P, Reis A, Tejasvi T, Trembath R, Voorhees JJ, Weidinger S, Weichenthal M, Wen X, Eriksson N, Kang HM, Hinds DA, Nair RP, Abecasis GR, Elder JT: | Nature Communications 8:15382, 2017. PMCID:PMC5458077. | |||
| 2017 | Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signaling. | Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Duffin KC, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN: | Human Molecular Genetics 26(21):4301-4313, 2017. PMID:28973304 PMCID:PMC5886170 | |||
| 2017 | Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. | Jadon DR, Sengupta R, Nightengale A, Lu H, Dunphy J, Green A, Elder JT, Nair RP, Korendowych E, Lindsay MA, McHugh NJ: | Arthritis Research and Therapy 19:210, 2017. PMCID:PMC5609020 | |||
| 2018 | Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting. | Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT. | J Rheumatol Suppl. 2018 Jun;94:54-61. | |||
| 2018 | GRAPPA 2017 Project Report. | Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC. | J Rheumatol Suppl. 2018 Jun;94:48-51. | |||
| 2018 | Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. | Furer V, Manasson J, Boehncke WH, Ritchlin CT. | J Rheumatol Suppl. 2018 Jun;94:4-10. | |||
| 2018 | The protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells. | Enerbäck C, Sandin C, Lambert S, Zawistowski MS, Stuart PE, Tsoi LC, Nair RP, Johnston A, Elder JT: | Scientific Reports 8(1):7043, 2018. PMID:29728633 PMCID:PMC5935702 | |||
| 2018 | Meta-analysis of RNA-seq datasets reveals an association between TRAJ23, psoriasis and ILI7A. | Merleev AA, Marusina AI, Ma C, Elder JT, Tsoi LC, Raychauduri S, Weidiner S, Wang EA, Adamopoulos IE, Luxardi G, Gudjonsson JE, Shimoda M, Maverakis E. | JCI Insight July 12;3(13) 2018. PMID:29997305 PMCID:PMC6124526 | |||
| 2018 | Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. | Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD: | Journal of Rheumatology Mar;45(3):378-384, 2018. PMID: 29419462 PMCID:PMC5845845 | |||
| 2018 | Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. | Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC: | Nature Communications 2018 Oct 9;9(1):4178. doi: 10.1038/s41467-018-06672-6, PMID:30301895 | |||
| 2018 | Neutrophil extracellular traps induce human Th17 cells: Effect of psoriasis-associated TRAF3IP2 genotype. | Lambert S, Hambro CA, Johnston A, Stuart PE, Elder JT: | Journal of Investigative Dermatology Dec 5. doi: 10.1016/j.jid.2018.11.021. [Epub ahead of print]. PMID: 30528823 | |||
| 2018 | A trans-ethnic Mendelian randomization study identifies causality of obesity on risk of psoriasis. | Ogawa K, Stuart PE, Tsoi LC, Suzuki K, Nair RP, Mochizuki H, Elder JT, Okada Y: | J Invest Dermatol, https://doi.org/10.1016/j.jid.2018.11.023 | |||
| 2018 | Evidence of a causal relationship between body mass index and psoriasis: a Mendelian Randomization study with implications for patient care. | Budu-Aggrey A, Brumpton A, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, Ferguson LD, Åberge Vie G, Palmer T, Fritsche LG, Løset M, Nielsen JB, Zhou W, Tsoi LC, Wood AR, Jones SE, Beaumont R, Saunes M, Romundstad PR, Siebert S, McInnes IB, Elder JT, Smith GD, Frayling TM, Åsvold, Brown SJ, Sattar N, Paternoster L: | PLoS Medicine, https://doi.org/10.1371/journal.pmed.1002739. PMID: 30703100. | |||
| 2018 | Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. American Journal of Medical Genetics Part B: | Tylee D, Sun J, Hess J, Tahir M, Sharma E, Malik R, Worrall B, Levine A, Martinson J, Nejentsev S, Speed D, Fischer A, Mick E, Walker B, Crawford A, Grant S, Polychronakos C, Bradfield J, Sleiman P, Hakonarson H, Ellinghaus E, Elder JT, Tsoi LC, Trembath R, Barker J Franke A, Dehghan A, Faraone S, Glatt S: | Neuropsychiatric Genetics, 2018 Oct;177(7):641-657. doi: 10.1002/ajmg.b.32652. Epub 2018 Oct 16. PMID: 30325587 PMCID: PMC6230304 | |||
| 2018 | PSUMMIT 1 and 2 Study Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials. | McInnes IB, Puig L, Gottlieb AB, Ritchlin C, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; | ||||
| 2018 | Psoriasis: Psychosomatic, somatopsychic, or both? | Kwon CW, Fried RG, Nousari Y, Ritchlin C, Tausk F. | Clin Dermatol. 2018 Nov - Dec;36(6):698-703. doi: 10.1016/j.clindermatol.2018.08.009. Epub 2018 Aug 16. | |||
| 2018 | Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. | McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM. | J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19. | |||
| 2018 | Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue. | Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH. | Arthritis Res Ther. 2018 Jul 11;20(1):139 | |||
| 2018 | Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. | Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD. | J Rheumatol. 2018 Oct;45(10):1389-1396. | |||
| 2018 | Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry | Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD. | RMD Open. 2018 Apr 25;4(1). | |||
| 2018 | Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). | Nash P, Mease PJ, McInnes IB, Rahman P, | Arthritis Res Ther. 2018 Mar 15;20(1):47. | |||
| 2018 | Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. | Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD. | J Rheumatol. 2018 Mar;45(3):378-384. | |||
| 2018 | Thy1 is a positive regulator of osteoblast differentiation and modulates bone homeostasis in obese mice. | Paine A, Woeller CF, Zhang H, de la Luz Garcia-Hernandez M, Huertas N, Xing L3 Phipps RP, Ritchlin CT. | FASEB J. 2018 Jun;32(6):3174-3183. | |||
| 2018 | Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions. | Paine A, Ritchlin C. | Calcif Tissue Int. 2018 May;102(5):559-574. | |||
| 2018 | Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. | Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. | Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. | |||
| 2018 | Ixekizumab for the treatment of psoriatic arthritis. | O'Rielly DD, Rahman P. (2018). | Expert Rev Clin Immunol. 2018 Dec(14(12)): 993-1002. | |||
| 2018 | Metabolomics of osteoarthritis: emerging novel markers and their potential clinical utility. | Zhai G, Randell EW, Rahman P. (2018). | Rheumatology (Oxford). 2018 Jan 24(24): 1-9. | |||
| 2018 | Genetics of psoriatic arthritis – an update. | O’Rielly D, Rahman P. (2018). | Medical Research Archives. 2018(6(3)): 1-26. | |||
| 2018 | Efficacy and Safetyof Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 WeekResults of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to TNF-Inhibitors. | Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Jarvinen P, Sanchez Burson J, Gaffney K, Lee, EB, Krishnan E, Santisteban S, Li X, ; Zhao F, Carlier H, Reveille J.(2018). | Arthritis Rheumatol. 2018 Oct 20(20): 1-7. | |||
| 2018 | Expression and Metabolomic Profiling in Axial Spondyloarthritis. | O'Rielly DD, Zhai G, Rahman P. (2018). | Current Rheumatology Reports. 20(8): 51. | |||
| 2018 | Real world evidence for using HLA-B27 SNP test for axial spondyloarthritis. | Nguyen HV, O'Rielly DD, Rahman P. (2018). | J Rheumatol. .2018 Sep 15(45(12)): 180408. | |||
| 2018 | Secukinumab improves active psoriatic arthritis symptomsand inhibits radiographic progression: primary results from the randomized, double-blind phase III FUTURE5. | Mease P, van der Heijde D, Landewe R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Nvarra S, Meiser K, Readie A, Pricop L, Abrams K. (2018). | Ann Rheum Dis.2018 Jun(77(6)): 890-897. | |||
| 2018 | Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treatedwith Golimumab. | Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman A, Nantel F. (2018). | Rheumatology (Oxford). 2018 Dec 4(57(8)): 1-7. | |||
| 2018 | Gaps in Diagnosis and Treatment of Cardiovascular RiskFactors in Patients with Psoriatic Disease: An International Multicenter Study. | Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R,Barac S, Feld J, Zisman D, Gladman DD. (2018). | J Rheumatol. 2018(Feb): 1-7. | |||
| 2018 | A review of ustekinumab in the treatment of psoriatic arthritis. | Roberts J, O’Rielly DD, Rahman P. (2018). | Immunotherapy. 10((5)): 361-372. | |||
| 2018 | Efficacy and safety of secukinumab administrationby autoinjedtor in patients withpsoriatic arthritis: results from a randomized, placebo-controlled trial(FUTURE 3). | Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, KajekarR, Mpofu S, Pricop L: FUTURE 3 Study Group. (2018). | Arthritis Res Ther. 2018 Mar 15; 20(1):47. 20((1)): 47. | |||
| 2018 | Geneticsignature to provide robust risk assessment of psoriaticarthritis development in psoriasis patients. | Patrick M, Stuart P, Raja K, Gudjonsson J, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerback C, Esko T, Franke A, Kang HM, Krueger G, Lim H, Rahman P, Rosen C, WeidingerS, Weichenthal M, Wen X, Voorhees J, Abecasis G, Gladman D, Nair R, Elder J, Tsoi L. (2018). | NatCommun. 2018 Oct 9(9(1)): 4178. | |||
| 2018 | Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. | Aljohani R, Polachek A, Ye J, Chandran V, Gladman DD. | J Rheumatol 2018;45:213-217. | |||
| 2018 | Addressing comorbidities in psoriatic arthritis. | Patel P, Rosen CF, Chandran V, Ye YJ, Gladman DD. | Rheumatol Int 2018;38:219-227. | |||
| 2018 | Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. | Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD. | J Rheumatol 2018;45:378-384. | |||
| 2018 | GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. | Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS. | Arthritis Rheumatol 2018:70:345-355. | |||
| 2018 | Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. | Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, Mehta NN. | Arthritis Rheumatol 2018;70:408-416. | |||
| 2018 | The Association between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. | Polachek A, Cook R, Chandran V, Abji F, Gladman D, Eder L. | Arthritis Rheumatol 2018;70:756-762. | |||
| 2018 | Th17 Gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. | Abji F, Pollock R, Liang K, Chandran V, Gladman DD. | Clin Exp Rheumatol 2018;36:486-489. | |||
| 2018 | Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. | Feld J, Chandran V, Haroon N, Inman R, Gladman D. | Nat Rev Rheumatol 2018;14:363-371. | |||
| 2018 | Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline? | Elalouf O, Chandran V. | Curr Rheumatol Rep 2018;20:36. | |||
| 2018 | Role of Methotrexate in the Management of Psoriatic Arthritis. | Elmamoun M, Chandran V. | Drugs 2018;78:611-619. | |||
| 2018 | Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers. | Mahendran SM, Chandran V. | Proteomes 2018;6(1). | |||
| 2018 | Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers. | Cretu D, Gao L, Liang K, Soosaipillai A, Diamandis EP, Chandran V. | Arthritis Care Res (Hoboken ) 2018;70:454-461. | |||
| 2018 | Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row? | Chandran V, Stecher L, Farewell V, Gladman DD. | Seminars Arthritis Rheum Online 2018/03/09. | |||
| 2018 | Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. | Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J Jr. | Br J Dermatol Online 2018/06/21. | |||
| 2018 | The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. | Zhou W, Chandran V, Cook R, Gladman DD, Eder L. | Semin Arthritis Rheum Online 2018/06/19. | |||
| 2018 | Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Seminars in arthritis and rheumatism. | Polachek A, Al-Johani R, Li S, Ye JY, Chandran V, Gladman D. | 2018; PubMed [journal] PMID: 30243758. | |||
| 2018 | Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: A population-based study. | Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R, Paterson JM, Cheng SY, Jabbari S, Campbell W, Bernatsky S, Gladman DD, Tu K. | Arthritis care & research. 2018; PubMed [journal] PMID: 30171803. | |||
| 2018 | Classification and Outcome Measures for Psoriatic Arthritis. | Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD. | Frontiers in medicine. 2018; 5:246. PubMed [journal] PMID: 30238006, PMCID: PMC6135872. | |||
| 2018 | Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. | Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis- Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC. | Nature communications. 2018; 9(1):4178. PubMed [journal] PMID: 30301895, PMCID: PMC6177414. | |||
| 2018 | Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. | Yap KS, Ye JY, Li S, Gladman DD, Chandran V. | Annals of the rheumatic diseases. 2018; 77(11):1573-1577. PubMed [journal] PMID: 30077991. | |||
| 2018 | Functional impairment measurement in psoriatic arthritis: Importance and challenges. | Mease P, Strand V, Gladman D. | Seminars in arthritis and rheumatism. 2018; 48(3):436-448. PubMed [journal] PMID: 30029795. | |||
| 2018 | Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row? | Chandran V, Stecher L, Farewell V, Gladman DD. | Seminars in arthritis and rheumatism. 2018; 48(3):430-435. PubMed [journal] PMID: 29724452. | |||
| 2018 | What Is Axial Psoriatic Arthritis? | Feld J, Chandran V, Gladman DD. | The Journal of rheumatology. 2018; 45(12):1611-1613. PubMed [journal] PMID: 30504477. | |||
| 2018 | Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. | Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD. | J Rheumatol. 2018 Mar;45(3):378-384. doi: 10.3899/jrheum.170379. Epub 2018 Feb 1. | |||
| 2018 | Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls [abstract]. | Thiele RG, Chiu YG, Huertas N, Li D, Feng C, Moorehead S, Bell C, Ritchlin CT. | Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/serum-cellular-and-imaging-markers-of-arthritis-in-psoriasis-patients-and-healthy-controls/. | |||
| 2019 | Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. | Magrey M, Ritchlin C. | Curr Opin Rheumatol. 2019 Mar;31(2):109-117. doi: 10.1097/BOR.0000000000000588. | |||
| 2019 | Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. | Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC. | Rheumatology (Oxford). 2019 Jan 3 | |||
| 2019 | Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials. | McInnes IB, Puig L, Gottlieb AB, Ritchlin C, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study. | J Rheumatol. 2019 Apr 1. | |||
| 2019 | Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial. | Mease PJ, Gladman DD2, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB. | Arthritis Rheumatol. 2019 Feb 12. | |||
| 2019 | Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. | Scher JU, Ogdie A, Merola JF, Ritchlin C. | Nat Rev Rheumatol. 2019 Mar;15(3):153-166 | |||
| 2019 | The association between occupational- related mechanical stress and radiographic damage in psoriatic arthritis. | Zhou W, Chandran V, Cook R, Gladman DD, Eder L. | Seminars in arthritis and rheumatism. 2019; 48(4):638-643. PubMed [journal] PMID: 30057322. | |||
| 2019 | Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. | Pollock RA, Zaman L, Chandran V, Gladman DD. | PloS one. 2019; 14(2):e0212043. PubMed [journal] PMID: 30779748, PMCID: PMC6380582. | |||
| 2019 | Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. | Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L. | The Journal of rheumatology. 2019; 46(3):266-273. PubMed [journal] PMID: 30385708. | |||
| 2019 | The development of a modified Psoriatic Arthritis Disease Activity Score (mPASDAS) using SF-12 as a measure of quality of life. | Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V. | Arthritis care & research. 2019; PubMed [journal] PMID: 30875460. | |||
| 2019 | Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. | Wakhlu A, Chandran V, Phumethum V, Shen H, Cook RJ, Gladman D. | Clinical rheumatology. 2019; 38(4):1063-1066. PubMed [journal] PMID: 30498874 | |||
| 2019 | Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. | Scher J., Ogdie A, Merola J, Ritchlin CT. | Nature Rev Rheum. 2019; 15:153. | |||
| 2019 | Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. | Budu-Aggrey, A., Brumpton, B., Tyrrell, J., Watkins, S., Modalsli, E.H., Celis-Morales, C., Ferguson, L.D., Vie, G.A., Palmer, T., Fritsche, L.G., et al. (2019). | PLoS Med 16, e1002739. | |||
| 2019 | Neutrophil Extracellular Traps Induce Human Th17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype. | Lambert, S., Hambro, C.A., Johnston, A., Stuart, P.E., Tsoi, L.C., Nair, R.P., and Elder, J.T. (2019). | J Invest Dermatol 139, 1245-1253. | |||
| 2019 | Differential accessibility of AP1-family binding sites in CD3-CD28-activated vs. resting T-cells [abstract]. | Zhang, Z., Tsoi, L.C., Nair, R.P., Stuart, P.E., Pique-Regi, R., Wen, R., and Elder, J.T. (2019). | J Invest Dermatol. | |||
| 2020 | The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report [abstract]. | Eder L, Lee K, Chandran V, Widdifield J, Drucker A, Ritchlin C, Rosen C, Cook R, Gladman D. | Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-prediction-of-psoriatic-arthritis-tool-presto-study-interim-report/. | |||
| 2020 | Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. | Rahmati S, O'Rielly DD, Li Q, Codner D, Dohey A, Jenkins K, Jurisica I, Gladman DD, Chandran V, Rahman P. | Sci Rep. 2020 Dec 10;10(1):21703. doi: 10.1038/s41598-020-78866-2. | |||
| 2020 | Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). | Li Q, Chandran V, Tsoi L, O'Rielly D, Nair RP, Gladman D, Elder JT, Rahman P. | Sci Rep. 2020 Mar 18;10(1):4925. | |||
| 2020 | Complexities in Genetics of Psoriatic Arthritis. | Rahmati S, Tsoi L, O'Rielly D, Chandran V, Rahman P. | Curr Rheumatol Rep. 2020 Mar 12;22(4):10. doi: 10.1007/s11926-020-0886-x. | |||
| 2020 | The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. | Fei Z, Perruccio AV, Ye JY, Gladman DD, Chandran V. | Rheumatology (Oxford). 2020;59:69-76. | |||
| 2020 | Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? | Feld J, Ye JY, Chandran V, Inman RD, Haroon N, Cook R, Gladman DD. | Rheumatology (Oxford) 2020;59:1340-1346. | |||
| 2020 | Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). | Li Q, Chandran V, Tsoi L, O’Rielly D, Gladman D, Elder JT, Rahman P. | Sci Rep. 2020;10(1):4925. | |||
| 2020 | Treating psoriatic arthritisto target:DefiningthePsoriaticArthritis DiseaseActivity Score that reflectsa state of minimal diseaseactivity. | Perruccio AV, GotM, Li S, Ye Y,Gladman DD, Chandran V. | Journal of Rheumatology. 2020;47:362-368. | |||
| 2020 | Development of a modifiedpsoriaticarthritis disease activity score using the Medical Outcomes Study Short Form 12 as a measure ofquality of life. | Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V. | Arthritis Care Res 2020;72:577-582. | |||
| 2020 | Mortality inpsoriatic arthritis: risk,causes of death, predictors of death. | Elaflouf O, Muntyanu A, PolachekA, Pereira D, Ye JY, Lee KA, Chandran V, Cook RJ, Gladman DD. | Seminars in Arthritis Rheumatol 2020;50:571-575. | |||
| 2020 | Liver Abnormalities in patients withpsoriatic arthritis. | Pakchotanon R, Ye Y, Cook RJ, Chandran V,Gladman DD. | J Rheumatol 2020;47:847-853. | |||
| 2020 | Predictive utility ofcardiovascular riskprediction algorithms in inflammatory rheumatic diseases: A systematic review. | Colaco K, Ocampo V, Ayala AP, Harvey P,Gladman D,Piguet V, Eder L. | J Rheumatol 2020;47:928-938. | |||
| 2020 | The relationshipbetween physical examination andultrasonography for large entheses isbest fortheAchilles tendon andpatellar tendon origin. | Aydin SZ, Bakirci S,Kaspoglu E, Castillo-Gallego C,Alhussain FA, Ash ZR, Kurum E,McGonagle D,Marzo-Ortega H,Gladman D, Eder L. | J Rheumatol 2020;47:1026-1030. | |||
| 2020 | Case Report ofRefractory Psoriatic Arthritis Achieving Remission Using Nigellasativa (Black Seed Oil) Extract. | Rida MA, Gladman DD. | J Rheumatol2020;47:1267. | |||
| 2020 | Declining levels ofserum CXCL10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: A new biomarker? | Abji F, Lee K,MathM, Pollock RA,MachharR, Cook RJ, Chandran V, Gladman DD. | British Journal of Dermatology. 2020;183:920-927. | |||
| 2020 | Remission in psoriatic arthritis: Definition and predictors. | Al Harbi S, Lee Ker-Ai, Chandran V, Cook R, Gladman DD. | Semin Arthritis Rheum 2020;50:1494-1400. | |||
| 2020 | The association between synovial fluid serineproteinase activity and response to intra-articular corticosteroid injection inpsoriatic arthritis. | Abji F, Ye JY, Cook RJ, Oikinomopoupos K, Chandran V. | Clin Rheumatol 2020;39:2355-2361 | |||
| 2020 | The phenotype of axial spondyloarthritis: is itdependent on HLA-B27 status? | Coates LC, Baraliakos X, Blanco FJ, Blanco-Morales E, Braun J, Chandran V, Luiz Fernandez-Sueiro J,FitzGerald O,Gallagher P,Gladman DD,Gubar E, Korotaeva T, Loginova E,Lubrano E, Mulero J, PintoJ, Queiro R,Sanz J, Szentpetery A, Helliwell PS. | Arthritis Care & Research(Hoboken). e 2020/02/26. | |||
| 2020 | Prevalence andfactors associated with osteoporosis and bonemineral density testing in psoriatic arthritis. | Kwok TSH, Sutton M, Yang YeJ, Pereira D, Chandran V,Gladman DD. | Arthritis Care Res(Hoboken)Online 2020/12/16. | |||
| 2020 | Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study. | Xia, J., Xie, S.Y., Liu, K.Q., Xu, L., Zhao, P.P., Gai, S.R., Guan, P.L., Zhao, J.Q., Zhu, Y.P., Tsoi, L.C., et al. (2020). | Ann Rheum Dis 79, 1460-1467. | |||
| 2020 | Differential gene expression and chromatin accessibility reveals Th17 polarization in skin-homing T cells [abstract]. | Zhang, X., Tsoi, L.C., Nair, R.P., Stuart, P.E., Wen, X., and Elder, J.T. (2020). | J Invest Dermatol. | |||
| 2020 | Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. | Ritchlin CT, Pennington SR, Reynolds NJ, FitzGerald O.J | Rheumatol Suppl. 2020 Jun;96:19-24. doi: 10.3899/jrheum.200122. | |||
| 2020 | Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. | Rahmati S, O'Rielly DD, Li Q, Codner D, Dohey A, Jenkins K, Jurisica I, Gladman DD, Chandran V, Rahman P. | Sci Rep. 2020 Dec 10;10(1):21703. doi: 10.1038/s41598-020-78866-2. | |||
| 2021 | Malignancy in psoriaticdisease: Results from prospective longintudinalcohorts. | Polachek A,MuntyanuA, Lee KA,Ye JY, ChandranV, Cook RJ, Gladman DD. | Semin ArthritisRheum 2021;51:144-149. | |||
| 2021 | Incidence of andRisk Factors for Heart Failure in Patients with Psoriatic Disease-A Cohort Study. | Koppikar S, Colaco K,Harvey P, Akhtari S, Chandran V,Gladman DD, CookR,Eder L. | Arthritis Care Res Online 2021/02/12. | |||
| 2021 | A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. | Luo, Y., Kanai, M., Choi, W., Li, X., Sakaue, S., Yamamoto, K., Ogawa, K., Gutierrez-Arcelus, M., Gregersen, P.K., Stuart, P.E., et al. (2021). | Nat Genet 53, 1504-1516. | |||
| 2021 | Large-Scale Imputation of KIR Copy Number and HLA Alleles in North American and European Psoriasis Case-Control Cohorts Reveals Association of Inhibitory KIR2DL2 with Psoriasis. | Ahn, R., Vukcevic, D., Motyer, A., Ntitham, J., Squire, D., Hollenbach, J.A., Norman, P.J., Ellinghaus, E., Nair, R.P., Tsoi, L.C., et al. (2021). | Frontiers in Immunology in press, Manuscript ID: 684326. | |||
| 2021 | International GWAS meta-analysis identifies 49 new psoriasis-associated genetic loci [abstract]. | Dand, N., and International-Psoriasis-GWAS-Consortium. (2021). | Br J Dermatol. | |||
| 2021 | Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. | Patrick, M.T., Zhang, H., Wasikowski, R., Prens, E.P., Weidinger, S., Gudjonsson, J.E., Elder, J.T., He, K., and Tsoi, L.C. (2021). | J Allergy Clin Immunol 147, 857-869 e857. | |||
| 2021 | Causal Relationship and Shared Genetic Loci between Psoriasis and Type 2 Diabetes through Trans-Disease Meta-Analysis. | Patrick, M.T., Stuart, P.E., Zhang, H., Zhao, Q., Yin, X., He, K., Zhou, X.J., Mehta, N.N., Voorhees, J.J., Boehnke, M., et al. (2021). | J Invest Dermatol 141, 1493-1502. | |||
| 2021 | Differential gene expression in psoriatic vs. normal T-cells is enhanced by CD3-CD28 activation [abstract]. | Zhang, Z., Zhao, Y., Tsoi, L.C., Nair, R.P., Stuart, P.E., Wen, X., and Elder, J.T. (2021). | J Invest Dermatol. | |||
| 2021 | Dysregulation of bile acids, lipids, and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites. | Paine A, Brookes,P, Bhattacharya S, Li D, Garcia-Hernande M, Tausk F, Ritchlin, CT . | (Presented at 2021 ACR meeting and in review at Arthritis and Rheumatology). | |||
| 2021 | National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments | Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. | ||||
| 2021 | Differences in oxylipin profile in psoriasis versus psoriatic arthritis. | Coras R, Kavanaugh A, Kluzniak A, Holt D, Weilgosz A, Aaron A, Quehenberger O, Ritchlin C, Guma M. | Arthritis Res Ther. 2021 Jul 24;23(1):200. doi: 10.1186/s13075-021-02575-y.PMID: 34303373 | |||
| 2021 | Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints | Łukasik Z, Gracey E, Venken K, Ritchlin C, Elewaut D. | Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv16-iv27. doi: 10.1093/rheumatology/keab385. | |||
| 2021 | Navigating the landscapes of psoriatic arthritis | Ritchlin C. | Semin Immunopathol. 2021 Apr;43(2):279-290. doi: 10.1007/s00281-021-00848-x. Epub 2021 Mar 15. | |||
| 2021 | Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. | Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L, Mease P, Reddy S, Ogdie A, Merola JF, Scher JU. | Nat Rev Rheumatol. 2021 Apr;17(4):238-243. doi: 10.1038/s41584-021-00578-2 | |||
| 2021 | New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine | Yan D, Gudjonsson JE, Le S, Maverakis E, Plazyo O, Ritchlin C, Scher JU, Singh R, Ward NL, Bell S, Liao W. | J Invest Dermatol. 2021 Sep;141(9):2112-2122.e3. doi: 10.1016/j.jid.2021.02.764. Epub 2021 Jul 22.PMID: 34303522 | |||
| 2021 | Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis | Scher JU, Ogdie A, Merola JF, Ritchlin C. | Arthritis Rheumatol. 2021 Sep;73(9):1574-1578. doi: 10.1002/art.41765. Epub 2021 Jul 28. | |||
| 2021 | Clinical and molecular significance of genetic loci associated with psoriatic arthritis. | O'Rielly DD, Rahman P. | Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101691. | |||
| 2021 | Insights into the pathogenesis of psoriatic arthritis from genetic studies. | Rahmati S, Li Q, Rahman P, Chandran V. | Semin Immunopathol. 2021 Apr;43(2):221-234. | |||
| 2021 | Genetic Epidemiology of Complex Phenotypes. | O'Rielly DD, Rahman P. | Methods Mol Biol. 2021;2249:335-367. | |||
| 2021 | Identifying Aspects of Public Attitudes Toward Whole Genome Sequencing to Inform the Integration of Genomics into Care. | Etchegary H, Pullman D, Simmonds C, Rabie Z, Rahman P. | Public Health Genomics. 2021;24(5-6):229-240. | |||
| 2021 | Small plaque psoriasis re-visited: A type of psoriasis mediated by a type-1 interferon pathway. | Khosravi-Hafshejani T, Ghoreishi M, Vera Kellet C, Crawford RI, Martinka M, Dutz JP. | Exp Dermatol. 2021 Dec 10. doi: 10.1111/exd.14513. Online ahead of print. PMID: 34890074 | |||
| 2021 | A Retrospective Study on the Effectiveness of Ixekizumab After Treatment with Secukinumab for Patients with Active Psoriatic Arthritis. | Darabian S, Badii M, Dutz J, Chan J. | Journal of Psoriasis and Psoriatic Arthritis 2021, Vol 0(0) 1-4. DOI:10.1177/24755303211063841 | |||
| 2021 | Combination Therapy with Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis. | Megan S, Yip A, Ziouzina O, Chan J, Dutz JP. | Journal of Clinical Rheumatology 2021 June; DOI: 10.1097/RHU.0000000000001767 PMID: 34176886 | |||
| 2021 | Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. | Colaco K, Lee KA, Akhtari S, Winer R, Welsh P, Sattar N, McInnes IB, Chandran V, Harvey P, Cook RJ, Gladman DD, Piguet V, Eder L. | Ann Rheum Dis 2021;80:1429–1435. | |||
| 2021 | Incidence of and risk factors for heart failure in patients with psoriatic disease - A cohort study. | Koppikar S, Colaco K, Harvey P, Akhtari S, Chandran V, Gladman DD, Cook R, Eder L. | Arthritis Care Res Online 2021/02/12. | |||
| 2021 | Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. | Wong A, Ye JY, Cook RJ, Gladman DD, Chandran C. | Arthritis Care Res Online 2021/03/05. | |||
| 2021 | Oligoarticular versus polyarticular psoriatic arthritis: A longitudinal study showing similar characteristics. | Gladman DD, Ye JY, Chandran V, Lee KA, Cook RJ. | J Rheumatol Online 2021/08/03. | |||
| 2021 | Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles [abstract]. | Cruz Correa O, Pollock R, Machhar R, Gladman D. | Arthritis Rheumatol 2021; 73 (suppl 10). https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-in-patients-with-psoriasis-using-dna-methylation-profiles/. | |||
| 2021 | Susceptibility Factors for Psoriatic Arthritis: Single-cell RNA-Sequencing of Patients with Psoriatic Disease. | Garrido AN, Machhar R, Cruz Correa O, Ganatra D, Crome SQ, Wither J, Jurisica I, Gladman DD. | Arthritis Rheumatol 2021; 73 (suppl 10) .https://acrabstracts.org/abstract/susceptibility-factors-for-psoriatic-arthritis-single-cell-rna-sequencing-of-patients-with-psoriatic-disease/. | |||
| 2021 | Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextraction-liquid chromatography-high-resolution mass spectrometry. | Looby N, Roszkowska A, Reyes-Garcés N, Yu M, Bączek T, Kulasingam V, Pawliszyn J, Chandran V. | Metabolomics 2021;17:59. | |||
| 2021 | The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. | Damian AC, Colaco K, Rohekar S, Boyd T, Chandran V, Gladman DD, Cook R, Eder L. | Semin Arthritis Rheum. 2021 Jun;51(3):547-552. | |||
| 2021 | Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis | Sarabia S, Farrer C, Yeung J, Jerome D, Cook RJ, Eder L. | ||||
| 2021 | Treatment persistence of biologics among patients with psoriatic arthritis. | Haddad A, Gazitt T, Feldhamer I, Feld J, Cohen AD, Lavi I, Tatour F, Bergman I, Zisman D. | Arthritis Res Ther. 2021 Jan 29; 23(1):44. | |||
| 2021 | The association of psoriatic arthritis with all-cause mortality and leading causes of death in psoriatic arthritis. | Haddad A, Saliba W, Lavi I, Batheesh A, Kasem S, Gazitt T, Feldhamer I, Cohen AD, Zisman D. | J Rheumatol. 2021 Jul 15 | |||
| 2021 | Implementation of the Treat-to-Target concept in evaluation of psoriatic arthritis patients. | Gazitt T, Elhija MA, Haddad A, Lavi I, Elias M, Zisman D | J Clin Med. 2021 Nov 30;10(23):5659 | |||
| 2022 | Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine-mapping in the MHC and genomewide. | Stuart, P.E., Tsoi, L.C., Nair, R.P., Ghosh, M., Kabra, M., Shaiq, P.A., Raja, G.K., Qamar, R., Thelma, B.K., Patrick, M.T., et al. (2022). | HGG Adv 3. | |||
| 2022 | Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation. | Martin, S., Tyrrell, J., Thomas, E.L., Bown, M.J., Wood, A.R., Beaumont, R.N., Tsoi, L.C., Stuart, P.E., Elder, J.T., Law, P., et al. (2022). | Elife 11. | |||
| 2022 | Relationship between periodontitis and psoriasis: A two-sample Mendelian randomization study. | Baurecht, H., Freuer, D., Welker, C., Tsoi, L.C., Elder, J.T., Ehmke, B., Leitzmann, M.F., Holtfreter, B., and Baumeister, S.E. (2022). | J Clin Periodontol. | |||
| 2022 | Pathophysiology of PsA, | Garcia-Hernandez M, Ritchlin CT. | The Rheumatologist 2022 (in press). | |||
| 2022 | Does biologic therapy impact the development of PsA among patients with psoriasis? | Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, Chen Y, Xie S, Choi H, Zhang Y, Scher JU, Ritchlin CT, Gelfand JM, Ogdie A. | Ann Rheum Dis. 2022 Jan;81(1):80-86. doi: 10.1136/annrheumdis-2021-220761. Epub 2021 Oct 6.PMID: 34615637 | |||
| 2022 | Public interest in unexpected genomic findings: a survey study identifying aspects of sequencing attitudes that influence preferences. | Etchegary H, Pullman D, Simmonds C, Rahman P. | J Community Genet. 2022 Apr;13(2):235-245. | |||
| 2022 | Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. | Colaco K, Lee KA, Akhtari S, Winer R, Welsh P, Sattar N, McInnes IB, Chandran V, Harvey P, Cook RJ, Gladman DD, Piguet V, Eder L. | Arthritis Rheumatol Online 2022/03/10. | |||
| 2022 | Psoriatic Arthritis and COVID-19 — Patient Perspectives in a Large Psoriatic Arthritis Cohort | Pirouzmand N, Pereira D, Sutton M, Mathew AJ, Chandran V, Gladman DD. | (Presented at CRA 2022) | |||
| 2022 | Effectiveness of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. | Mathew AJ, Sutton M, Pereira D, Gladman DD, Chandran V. | J Rheumatology 2022 (accepted). | |||
| 2022 | miR-190a-5p and miR-26b-5p are potential miRNA Biomarkers for psoriatic arthritis. | Cruz-Correa OF, Ganatra D, Garrido AN, Machhar R, Lively S, Kapoor M, Gladman DD. | Presented at CRA 2022. | |||
| 2022 | miRNA biomarkers for methotrexate response in psoriatic arthritis patients. | Cruz Correa OF, Ganatra D, Garrisdo AN, Machhar R, Lively Star, Kapoor M, Gladman DD. | Presented at CRA 2022. | |||
| 2022 | Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases. | Dayam RM, Law JC, Goetgebuer RL, Chao GYC, Abe KT, Sutton M, Finkelstein N, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Rymaszewski K, Milgrom R, Ganatra D, Batista NV, Girard M, Lau I, Law R, Cheung MW, Rathod B, Kitaygorodsky J, Samson R, Hu Q, Hardy WR, Haroon N, Inman RD, Piguet V, Chandran V, Silverberg MS, Gingras AC, Watts TH. | JCI Insight 2022 (Accepted). | |||
| 2022 | Defining Imaging Sub-phenotypes of Psoriatic Arthritis: Integrative Analysis of Imaging Data and Gene Expression in a PsA Patient Cohort. | Eder L, Li Q, Rahmati S, Rahman P, Jurisica I, Chandran V. | Rheumatology (Oxford). 2022 Feb 14 E-publication | |||
| 2022 | Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings. | Diaz P, Feld J, Eshed I, Eder L. | RMD Open. 2022;8(1):e002011. | |||
| 2022 | The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study. | Gazitt T, Pesachov J, Lavi I, Elias M, Haddad A, Feldhamer I, Cohen AD, Saliba W, Zisman D | Arthritis Res Ther. 2022 Jan 7 | |||
| 2022 | High dimensional analyses of circulating immune cells in psoriatic arthritis detects elevated phosphorylated STAT3. | Macaubas C, Rahman SS, Lavi I, Haddad A, Elias M, Sengupta D, Zisman D Mellins ED. | Front Immunol. 2022 Jan 11;12:758418 | |||
| 2022 | Amphiregulin carboxy-terminal domain is required for autocrine keratinocyte growth. | Stoll SW, Johnson JL, Rittie L, Elder JT: | Journal of Investigative Dermatology, 130(8):2031-40, 2010. PMCID: PMC3072808. | |||
| 2022 | Effect of Adalimumab on Joint Disease Features of Patients with Psoriatic Arthritis Detected by MRI. | Anandarajah A, Ory P, Salonen D, Feng C, McIllraith M, Ritchlin CT. | Ann Rheum Dis. PMID. 19204015. |